List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME		VAR NAME
ABCA4	Stargardt disease 1 inc Cone-rod dystrophy 3	cluding	NM_000350.3:c.6449G>A, NM_000350.3:c.6394G>T, NM_000350.3:c.6320G>A, NM_000350.3:c.6179T>G, NM_000350.3:c.6148G>C, NM_000350.3:c.6182G>A, NM_000350.3:c.5181C>G, NM_000350.3:c.5181C>G, NM_000350.3:c.5181C>G, NM_000350.3:c.5181C>G, NM_000350.3:c.5184C>G, NM_000350.3:c.5184C>G, NM_000350.3:c.5146G>A, NM_000350.3:c.5146G>A, NM_000350.3:c.5146G>A, NM_000350.3:c.5146G>A, NM_000350.3:c.5146G>A, NM_000350.3:c.4139C>F, NM_000350.3:c.4139C>F, NM_000350.3:c.4139C>F, NM_000350.3:c.3140350.3:c.4139C>F, NM_000350.3:c.3140350.3:c.4139C>F, NM_000350.3:c.31063C>F, NM_000350.3:c.3083C>F, NM_000350.3:c.3083C>F, NM_000350.3:c.3083C>F, NM_000350.3:c.3206C>F, NM_000350.3:c.2162C>F, NM_000350.3:c.2160C>F, NM_000350.3:c.2160C>F, NM_000350.3:c.2160C>F, NM_000350.3:c.1260C>F, NM_000350.3:c.1260C>F, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.1374C=F, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.139A:C>A, NM_000350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.1374C=F, NM_00350.3:c.132550=F, NM_00350.3:c.132550=F, NM_00350.3:c.132550=F, NM_00350.3:c.132550=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.132550=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.13250=F, NM_00350.3:c.342C=F, NM_00350.3:c.13250=F, NM_00350.3:c.342C=F, NM_00350.3:c.13250=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.13250=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=F, NM_00350.3:c.342C=
ACAD9	Mitochondrial complex deficiency	ĸI	NM_000350.3:c:286A>G, NM_000350.3:c.67-2A>G, NM_000350.3:c.52C>T NM_014049.5:c.23delT, NM_014049.5:c.130T>A, NM_014049.5:c.358delT, NM_014049.5:c.453+16>A, NM_014049.5:c.7976S-A, NM_014049.5:c.376G>C, NM_014049.5:c.1240C>T, NM_014049.5:c.1249C>T, NM_014049.5:c.1594C>T
ACADM	Medium-chain acyl-Co dehydrogenase deficie		NM_000016.6:c.127G>A, NM_000016.6:c.250C>T, NM_000016.6:c.287-2A>G, NM_000016.6:c.362C>T, NM_000016.6:c.446_449delTGAC, NM_000016.6:c.47C>A, NM_000016.6:c.47G>T, NM_000016.6:c.61G NM_000016.6:c.617G>A, NM_000016.6:c.683C>A, NM_000016.6:c.734C>T, NM_000016.6:c.79TA>G, NM_000016.6:c.799G>A, NM_000016.6:c.815_827delTTGCAATGGGAGC, NM_000016.6:c.890A>G, NM_000016.6:c.984delG, NM_000016.6:c.985A>G, NM_000016.6:c.1100_1103delAGTT
ACADS	Acyl-CoA dehydrogena chain, deficiency of	se, short-	NM_000017.4:c.136C>T, NM_000017.4:c.314T>A, NM_000017.4:c.319C>T, NM_000017.4:c.417G>C, NM_000017.4:c.529T>C, NM_000017.4:c.561_568deICAATGCCT, NM_000017.4:c.826G>A, NM_000017.4:c.1095G>T, NM_000017.4:c.1108A>G, NM_000017.4:c.1147C>T
ACADSB	2-methylbutyrylglycinu	ıria	NM_001609.4:c.303+1G>A, NM_001609.4:c.443C>T, NM_001609.4:c.621G>A, NM_001609.4:c.763C>T, NM_001609.4:c.1159G>A
ACADVL	Very long-chain acyl-Co dehydrogenase (VLCAE deficiency		NM_000018.4:c.278-1G>A, NM_000018.4:c.295_296delAC, NM_000018.4:c.343-1delG, NM_000018.4:c.400C-T, NM_000018.4:c.477+1G>C, NM_000018.4:c.520G>A, NM_000018.4:c.685C>T, NM_000018.4:c.390_892delAGA, NM_000018.4:c.109GCT, NM_000018.4:c.1097G>A, NM_000018.4:c.106T>C, NM_000018.4:c.1319_1141delAGG, NM_00018.4:c.1182+1G>A, NM_000018.4:c.1387C_1NM_000018.4:c.136GO>A, NM_000018.4:c.1373_1374InS-C, NM_000018.4:c.1385_1386insG, NM_000018.4:c.1406G>A, NM_000018.4:c.1468G>C, NM_000018.4:c.1385_1386insG, NM_000018.4:c.1406G>A, NM_000018.4:c.1468G>C, NM_000018.4:c.1385_1386insG, NM_000018.4:c.1837C>T, NM_000018.4:c.1843C>T, NM_00018.4:c.1844G>A, NM_000018.4:c.1385_1386insG, NM_000018.4:c.1837C>T, NM_000018.4:c.1843C>T, NM_000018.4:c.1844G>A, NM_000018.4:c.1832+16=A, NM_000018.4:c.1837C>T, NM_000018.4:c.1843C>T, NM_000018.4:c.1844G>A, NM_000018.4:c.1832+16=A, NM_000018.4:c.1837C>T, NM_000018.4:c.1843C>T, NM_000018.4:c.18446>A, NM_000018.4:c.1828+100018.4:c.1844G>A, NM_000018.4:c.1844C>T, N
ACAT1	Beta-Ketothiolase Defi	-	NM_000019.4:c.2T>A, NM_000019.4:c.409_416delTCTCAAAG, NM_000019.4:c.547G>A, NM_000019.4:c.622C>T, NM_000019.4:c.904delA, NM_000019.4:c.1031_1033delAAG, NM_000019.4:c.1082_1083insA, NM_000019.4:c.1136G>T, NM_000019.4:c.1138G>A
ACOX1	Acyl-CoA Oxidase I Def		NM_004035.7;c.832A>G, NM_004035.7;c.591delG, NM_004035.7;c.532G>T
ADA	Adenosine deaminase	deficiency	NM_000022.4:c:986C>T, NM_000022.4:c:956_960deIAAGAG, NM_000022.4:c:890C>A, NM_000022.4:c:872C>T, NM_000022.4:c:632G>A, NM_000022.4:c:320T>C, NM_000022.4:c:247G>A, NM_000022.4:c:226C>T
ADAMTS2	Ehlers-Danlos syndrom VII-C	ne, type	NM_014244.5:c.2384G>A
AGA	Aspartylglucosaminuria	а	NM_000027.4:c.904G>A, NM_000027.4:c.800dupT, NM_000027.4:c.755G>A, NM_000027.4:c.488G>C, NM_000027.4:c.302C>T, NM_000027.4:c.214T>C
AGL	Glycogen storage disea (Cori or Forbes disease	-	NM_000642.3:c.17_18deIAG, NM_000642.3:c.16C>T, NM_000642.3:c.112A>G, NM_000642.3:c.294-2A>T, NM_000642.3:c.1222C>T, NM_000642.3:c.1481G>A, NM_000642.3:c.1485deT, NM_000642.3:c.1783C>T, NM_000642.3:c.1299deIC, NM_000642.3:c.2039G>A, NM_000642.3:c.290C>T, NM_000642.3:c.3214_3215deIGA, NM_000642.3:c.3980G>A, NM_000642.3:c.4260-12A>G, NM_000642.3:c.4260-16>T, NM_000642.3:c.4342G>C, NM_000642.3:c.4454deIT, NM_000642.3:c.4258.4529insA
AGPS	Rhizomelic Chondrody Punctata, Type 3	splasia	NM_003659.4:c.926C>T, NM_003659.4:c.1256G>A, NM_003659.4:c.1406T>C, NM_003659.4:c.1703C>T
AGXT	Hyperoxaluria, primary	/, type 1	NM_000030.3:c.25_26insC, NM_000030.3:c.32C>A, NM_000030.3:c.121G>A, NM_000030.3:c.166-2A>G, NM_000030.3:c.456>A, NM_000030.3:c.322T>C, NM_000030.3:c.456T>A, NM_000030.3:c.506G>A, NM_000030.3:c.506G>A, NM_000030.3:c.506G>A, NM_000030.3:c.507 C, NM_000030.3:c.507 C, NM_000030.3:c.507 C, NM_000030.3:c.507 C, NM_000030.3:c.507 C, NM_000030.3:c.507 C, NM_000030.3:c.731T>C, NM_000030.3:c.73005 NM_000030.3:c.731T>C, NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.731T>C, NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_000030.3:c.73005 NM_00
ALDOB	Hereditary fructose Int	olerance	NM_000035.4:c.1067C>A, NM_000035.4:c.1027T>C, NM_000035.4:c.1013C>T, NM_000035.4:c.1005C>G, NM_000035.4:c.720C>A, NM_000035.4:c.612T>A, NM_000035.4:c.524C>A, NM_000035.4:c.448G>C, NM_000035.4:c.4242T>C, NM_000035.4:c.360_363delCAAA, NM_000035.4:c.178C>T, NM_000035.4:c.136A>T, NM_000035.4:c.113-1_115delGGTA, NM_000035.4:c.10C>T, NM_000035.4:c.27>C
ALG6	Congenital Disorder of Glycosylation, Type 1C		NM_013339.4:c.53G>A, NM_013339.4:c.316C>T, NM_013339.4:c.495-3C>G, NM_01339.4:c.495-3C>G, NM_01339.4:c.495-3C <ac>G, NM_01300.4:C^AC-3C<ac>G, NM_01300.</ac></ac>



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
ALMS1	Alstrom syndrome	NM_001378454.1:c. 888_904delTCAGCACCCGGTTATAG, NM_001378454.1:c.157_1573delCTCInsT, NM_001378454.1:c.8161C>T, NM_001378454.1:c.8380C>T, NM_001378454.1:c.13908-1G>A, NM_001378454.1:c.1057_610577delCT, NM_001378454.1:c.1072delC, NM_001378454.1:c.11311_1314delAGAG, NM_001378454.1:c.11446C-T, NM_001378454.1:c.11448_11449insA, NM_001378454.1:c.11446C-T, NM_001378454.1:c.11448_11449insA, NM_001378454.1:c.12436C>T, NM_001378454.1:c.12442C>T
ALPL	Hypophosphatasia, inf	Antile NM_000478.6:c:98C>T, NM_000478.6:c:211C>T, NM_000478.6:c:212G>C, NM_000478.6:c:32G>T, NM_000478.6:c:346G>A, NM_000478.6:c:2005A, NM_000478.6:c:256G>A, NM_000478.6:c:756A, NM_000478.6:c:2005A, NM_000478.6:c:341C>T, NM_000478.6:c:355C>A, NM_000478.6:c:315C, NM_000478.6:c:21001G>A, NM_000478.6:c:313G>T, NM_000478.6:c:1250A>G, NM_000478.6:c:1306T>C, NM_000478.6:c:1366G>A, NM_000478.6:c:1574delG
AMT	Glycine encephalopath related)	y (AMT- NM_000481.4:c.959G>A, NM_000481.4:c.826G>C, NM_000481.4:c.806G>A, NM_000481.4:c.574C>T, NM_000481.4:c.259-1G>C, NM_000481.4:c.139G>A, NM_000481.4:c.125A>G
AR	Androgen insensitivity syndrome, X-Linked	NM_000044.6:c.340C>T, NM_000044.6:c.1769-11T>A, NM_000044.6:c.1771A>T, NM_000044.6:c.1937C>A, NM_000044.6:c.2323C>T, NM_000044.6:c.2391G>A, NM_000044.6:c.2395C>G, NM_000044.6:c.2567G>A, NM_000044.6:c.2650A>T
ARG1	Argininemia	NM_000045.4:c.32T>C, NM_000045.4:c.61C>T, NM_000045.4:c.365G>A, NM_000045.4:c.413G>T, NM_000045.4:c.703G>C, NM_000045.4:c.869C>G, NM_000045.4:c.871C>T
ARSA	Metachromatic leukod	NM_00487.6:c.1175G-A, NN_000487.6:c.1174C-T, NM_000487.6:c.1150G-A, NM_000487.6:c.1125G-A, NN_000487.6:c.1108-ZA-G, NM_000487.6:c.991G-T, NM_000487.6:c.938G-T, NM_000487.6:c.991G-X, NM_000487.6:c.938G-A, NM_000487.6:c.937C-T, NM_000487.6:c.931G-A, NM_000487.6:c.991G-X, NM_000487.6:c.838G-A, NM_000487.6:c.869G-T, NM_000487.6:c.956G-A, NM_000487.6:c.891G-X, NM_000487.6:c.827C-T, NM_000487.6:c.53G-A, NM_000487.6:c.932G-A, NM_000487.6:c.971G-A, NM_000487.6:c.827C-T, NM_000487.6:c.53G-A, NM_000487.6:c.582detC, NM_000487.6:c.737G-A, NM_000487.6:c.527C-T, NM_000487.6:c.583detT, NM_000487.6:c.582detC, NM_000487.6:c.5421A, NM_000487.6:c.237C-T, NM_000487.6:c.257G-A, NM_000487.6:c.582detC, NM_000487.6:c.323G-A, NM_000487.6:c.293C-T, NM_000487.6:c.257G-A, NM_000487.6:c.195detC, NM_000487.6:c.342detG
ARSB	Mucopolysaccharidosis (Maroteaux-Lamy)	S, Type VI NM_00046.5:c.15626-A, NM_00046.5:c.1438dupG, NM_00046.5:c.1626CT, NM_00046.5:c.1214G-A, 00046.5:c.17143-GC, NM_00046.5:c.1143-GS, NM_00046.5:c.1143-GS, NM_00046.5:c.1143-GS, NM_00046.5:c.937C-G, NM_00046.5:c.9321delA, NM_00046.5:c.937C-G, NM_00046.5:c.9321delA, NM_00046.5:c.9321delA, NM_00046.5:c.9321delA, NM_00046.5:c.9321delA, NM_00046.5:c.9321delA, NM_00046.5:c.9321delA, NM_00046.5:c.9320-G, NM_00046.5:c.9300-G, NM_00046.5:c.930-G, NM_
ASL	Argininosuccinic acidu	ia NM_000048.4:c.35G>A, NM_000048.4:c.337C>T, NM_000048.4:c.346C>T, NM_000048.4:c.332C>T, NM_000048.4:c.437G>A, NM_000048.4:c.3476>A, NM_000048.4:c.57C, NM_000048.4:c.557C>A, NM_000048.4:c.5325A, NM_000048.4:c.597A, NM_000048.4:c.576A, NM_000048.4:c.578G>A, NM_000048.4:c.507A, NM_000048.4:c.576A, NM_000048.4:c.103205A, NM_000048.4:c.507A, NM_000048.4:c.135C>A, NM_000048.4:c.5725A, NM_000048.4:c.133205A, NM_000048.4:c.5725A, NM_000048.4:c.135C>T, NM_000048.4:c.1255_1256delCT, NM_000048.4:c.1366_1367insG, NM_000048.4:c.1366C>T
ASPA	Canavan disease	NM_000049.4:c.212G>A, NM_000049.4:c.433-2A>G, NM_000049.4:c.654C>A, NM_000049.4:c.693C>A, NM_000049.4:c.838C>T, NM_000049.4:c.854A>C, NM_000049.4:c.863A>G, NM_000049.4:c.914C>A
ASS1	Citrullinemia type I	NM_054012.4:c.40G>A, NM_054012.4:c.53C>T, NM_054012.4:c.256C>T, NM_054012.4:c.257G>A, NM_054012.4:c.323G>T, NM_054012.4:c.349G>A, NM_054012.4:c.330G>A, MM_054012.4:c.421-2A>G, NM_054012.4:c.470G>A, NM_054012.4:c.349G>A, NM_054012.4:c.533T>C, NM_054012.4:c.533G>A, NM_054012.4:c.571G>A, NM_054012.4:c.787O>A, NM_054012.4:c.733G>T, NM_054012.4:c.533G>A, NM_054012.4:c.805G>A, NM_054012.4:c.787A, NM_054012.4:c.323G>T, NM_054012.4:c.333G>A, NM_054012.4:c.805G>A, NM_054012.4:c.787A, NM_054012.4:c.323G>T, NM_054012.4:c.333G>A, NM_054012.4:c.805G>A, NM_054012.4:c.1045C>T, NM_054012.4:c.323G>T, NM_054012.4:c.336G>A, NM_054012.4:c.910C>T, NM_054012.4:c.1045G>T, NM_054012.4:c.326G>A, NM_054012.4:c.970+5G>A, NM_054012.4:c.1085G>T, NM_054012.4:c.1087C>T, NM_054012.4:c.1088G>A, NM_054012.4:c.1168G>A, NM_054012.4:c.1194-1G>C
ΑΤΡ7Α	Menkes Syndrome, X-L	INKed NM_000052.7:c.1639C>T, NM_000052.7:c.1972_1973insTGTT, NM_000052.7:c.2531G>A, NM_000052.7:c.2938C>T, NM_000052.7:c.2981C>T, NM_000052.7:c.3255_3256de1AC, NM_000052.7:c.3294+2T>G, NM_000052.7:c.3911A>G, NM_000052.7:c.3914_3920de1ACTCCCC, NM_000052.7:c.3931A>G
АТР7В	Wilson disease	NM_000053.4:c.4301C>T, NM_000053.4:c.4135C>T, NM_000053.4:c.4088C>T, NM_000053.4:c.4058G>A, NM_000053.4:c.3909A>G, NM_000053.4:c.3909A>G, NM_000053.4:c.3909A>G, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.3908A>C, NM_000053.4:c.2975C>T, NM_000053.4:c.2972C>T, NM_000053.4:c.2923C>T, NM_000053.4:c.2975C>T, NM_000053.4:c.2975C>T, NM_000053.4:c.2755C>G, NM_000053.4:c.2755C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T, NM_000053.4:c.2955C>T,



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

	VAR NAME
L	
e syrup urine disease	e, type NM_000709.4:c.14delT, NM_000709.4:c.632C>T, NM_000709.4:c.659C>T, NM_000709.4:c.740_741insT, NM_000709.4:c.761C>A, NM_000709.4:c.7365C>T, NM_000709.4:c.740_741insT, NM_000709.4:c.761C>A, NM_000709.4:c.932G>C, NM_000709.4:c.932G>C, NM_000709.4:c.932G>C, NM_000709.4:c.929C>G, NM_000709.4:c.94c-942C>T, NM_000709.4:c.929C>G, NM_000709.4:c.924C>T, NM_000709.4:c.1036C>T, NM_000709.4:c.1037G>A, NM_000709.4:c.1234G>A
e syrup urine disease	e, type NM_183050.4:c.302G>A, NM_183050.4:c.342T>G, NM_183050.4:c.344-1G>A, NM_183050.4:c.356T>G, NM_183050.4:c.397T>G, NM_183050.4:c.398C>G, NM_183050.4:c.308C>G, NM_183050.4:c.308C>G, NM_183050.4:c.308C>G, NM_183050.4:c.309G>A, NM_183050.4:c.348C>G, NM_183050.4:
ILE syndrome	NM_001079866.2:c.103G>C, NM_001079866.2:c.133C>T, NM_001079866.2:c.148A>G, NM_001079866.2:c.166C>T, NM_001079866.2:c.5232A>G, NM_001079866.2:c.547C>T, NM_001079866.2:c.545A, NM_001079866.2:c.50C, T, NM_001079866.2:c.696deIT, NM_001079866.2:c.830G>A, NM_001079866.2:c.1057G>A
ni anemia, Group J	NM_032043.3:c.3209C>A, NM_032043.3:c.2990_2993delCAAA, NM_032043.3:c.2392C>T, NM_032043.3:c.2237_2240delTCAA, NM_032043.3:c.1702_1703delAA, NM_032043.3:c.1045G>C, NM_032043.3:c.502C>T, NM_032043.3:c.139C>G
er syndrome, type 4a	MM_057176.3:c.1A>T, NM_057176.3:c.3G>A, NM_057176.3:c.10G>T, NM_057176.3:c.23C>T, NM_057176.3:c.23G>A, NM_057176.3:c.23G>T, NM_057176.3:c.35T>C, NM_057176.3:c.139G>A
idase Deficiency	NM_001370658.1:c.124G>A, NM_001370658.1:c.175C>T, NM_001370658.1:c.274G<, NM_001370658.1:c.383G>A, NM_001370658.1:c.523A>G, NM_001370658.1:c.535G>A, NM_001370658.1:c.593A>G, NM_001370658.1:c.532A>G, NM_001370658.1:c.535G>A, NM_001370658.1:c.593A>G, NM_001370658.1:c.537LC>T, NM_001370658.1:c.535G>A, NM_001370658.1:c.734A>T, NM_001370658.1:c.537A>G, NM_001370658.1:c.637C>T, NM_001370658.1:c.734A>T, NM_001370658.1:c.537A>G, NM_001370658.1:c.637C>T, NM_001370658.1:c.734A>T, NM_001370658.1:c.1237A>G, NM_001370658.1:c.1279C>T, NM_001370658.1:c.1046C>T, NM_001370658.1:c.1200APC, NM_001370658.1:c.1279C>T, NM_001370658.1:c.1292G>A, NM_001370658.1:c.1200APC, NM_001370658.1:c.1235C>T, NM_001370658.1:c.1247_1451delGGGAT, NM_001370658.1:c.1471C>G, NM_001370658.1:c.1535C>T, NM_001370658.1:c.1552C>T
ed growth hormone ency, Type III, X-link	ed NM_000061.3:c.1906>7, NM_000061.3:c.1839>A, NM_000061.3:c.18380>A, NM_000061.3:c.1820<>A, NM_000061.3:c.1820<>A, NM_000061.3:c.1766A>G, NM_000061.3:c.1559A, NM_000061.3:c.1558>C, NM_000061.3:c.1558<>C, NM_000061.3:c.1515>C, NM_000061.3:c.1558>C, NM_000061.3:c.1223>C, NM_00061.3:c.1223>C, NM_00061.3:c.1555>C, NM_000061.3:c.1223>C, NM_00061.3:c.1223>C, NM_000061.3:c.1223>C, NM_000061.3:c.1233>C, NM_000061.3:c.1233>C, NM_000061.3:c.1233>C, NM_000061.3:c.12233>C, NM_0000050, NM_0000
ular dystrophy, limb omal recessive 1	-girdle, NM_000070.3:c.133G>A, NM_000070.3:c.220_221insT, NM_000070.3:c.246G>A, NM_000070.3:c.257C>T, NM_000070.3:c.529C+T, NM_000070.3:c.549delA, NM_000070.3:c.552-T, NM_000070.3:c.576G>A, NM_000070.3:c.597_61idel6TTCTGAATGCTCTT, NM_000070.3:c.567C>T, NM_000070.3:c.576G>A, NM_000070.3:c.146G>A, NM_000070.3:c.1456C>T, NM_000070.3:c.1319delG, NM_000070.3:c.1459_1602delGAGC, NM_000070.3:c.1610A>G, NM_000070.3:c.1315G>A, NM_000070.3:c.1473_1745+1delTGAG, NM_00070.3:c.1788_1789insA, NM_000070.3:c.1324GA, NM_000070.3:c.2120A, NM_000070.3:c.2212C>T, NM_00070.3:c.2306S>A, NM_000070.3:c.2248_2249insCAGT, NM_000070.3:c.2236S>A, NM_000070.3:c.2248_2249insCAGT, NM_000070.3:c.2326_2363delAGinsTCATCT
ocystinuria	NM_000071.3:c.1616T>C, NM_000071.3:c.1471C>T, NM_000071.3:c.1397C>T, NM_000071.3:c.1379C>T, NM_000071.3:c.1330C>A, NM_000071.3:c.1365C>T, NM_000071.3:c.1265C>T, NM_000071.3:c.13150A>G, NM_000071.3:c.13150A>G, NM_000071.3:c.1056C>T, NM_000071.3:c.1056C>T, NM_000071.3:c.9265C>A, NM_000071.3:c.9595C>C, NM_000071.3:c.9365C>A, NM_000071.3:c.9572C>T, NM_000071.3:c.9265C>A, NM_000071.3:c.976C>A, NM_000071.3:c.9335C>C, NM_000071.3:c.545C>T, NM_000071.3:c.3257C>T, NM_000071.3:c.9265C>A, NM_000071.3:c.415C>A, NM_000071.3:c.415C>A, NM_000071.3:c.415C>A, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>A, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_00071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_00071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000071.3:c.4572C>T, NM_000
ess, autosomal rece	SSIVE NM_022124.6:c.146-2A>G, NM_022124.6:c.189delC, NM_022124.6:c.288+1G>A, NM_022124.6:c.902G>A, NM_022124.6:c.1858+2T>G, NM_022124.6:c.1814(C>A, NM_022124.6:c.3293A>G, NM_022124.6:c.3515_3518delCATC, NM_022124.6:c.3579+2T>C, NM_022124.6:c.4504(C>T, NM_022124.6:c.52376>A, NM_022124.6:c.56375(C>K), NM_022124.6:c.56375(C>K), NM_022124.6:c.56375(C>K), NM_022124.6:c.56375(C>K), NM_022124.6:c.6442(C>A, NM_022124.6:c.7603C>A, NM_022124.6:c.6392delC, NM_022124.6:c.9319+1_9319+4delGTAA, NM_022124.6:c.9565C>T
athy	NM_025114.4:c.7394_7395delAG, NM_025114.4:c.7341dupA, NM_025114.4:c.7324G>T, NM_025114.4:c.6798G>A, NM_025114.4:c.6645+1G>A, NM_025114.4:c.5624G NM_025114.4:c.645645(A, NM_025114.4:c.5686G), NM_025114.4:c.561_5646(A, NM_025114.4:c.496), NM_025114.4:c.4962_4963delAA, NM_025114.4:c.496C>A, NM_025114.4:c.49545(A, NM_025114.4:c.496), NM_025114.4:c.49545(A, NM_025114.4:c.4954), NM_025114.4:c.496(A, NM_025114.4:c.496), NM_025114.4:c.4965(A, NM_025114.4:c.496), NM_025114.4:c.4965(A, NM_025114.4:c.496), NM_025114.4:c.4965(A, NM_025114.4:c.496), NM_025114.4:c.4965(A, NM_025114.4:c.496), NM_025114.4:c.1665_1666(A, NM_025114.4:c.1665_1666(A, NM_025114.4:c.1665_166), NM_025114.4:c.1665_166(A, NM_025114.4:c.1665_16), NM_025114.4:c.166_16), NM_025114.4:c.166_1
tis pigmentosa 26	NM_201548.5:c.1553_1569dupTTATCAGTCTTTATGGA, NM_201548.5:c.1012C>T, NM_201548.5:c.847C>T, NM_201548.5:c.780delT, NM_201548.5:c.769C>T, NM_201548.5:c.312delA
	e syrup urine disease ILE syndrome ni anemia, Group J er syndrome, type 4a idase Deficiency ed growth hormone ency, Type III, X-linko ular dystrophy, limb omal recessive 1 ocystinuria ess, autosomal rece



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
CFTR	Cystic fibrosis	 NM. 000892.4: C1955.CT, NM. 000892.4: C1956.AN, NM. 000892.4: C1956, C1956, NM.



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE DISEASE NAME	VAR NAME
	NM. 000492.4:c1209-16-T, NM. 000492.4:c1210.34, 1210-3364CTG, NM. 000492.4:c1210.34, 1210-3104 DidelTGTG, NM. 000492.4:c1210.35, 1210-3416CTG, NM. 000492.4:c1210.35, 1210-3416CTGG, NM. 000492.4:c1210-11 NM. 000492.4:c1210-11.210-1104 MM. 000492.4:c1210-11.210-1104 NM. 000492.4:c1210-11.210-1104 NM. 000492.4:c1210-11.210-1104 NM. 000492.4:c1210-11.210-1104 NM. 000492.4:c1210-11.210-1104 NM. 000492.4:c1211-12354 NM. 000492.4:c1211-12354 NM. 000492.4:c1211-12354 NM. 000492.4:c1211-12354 NM. 000492.4:c1211-12354 NM. 000492.4:c1215-12364 NM. 000492.4:c1215-12364 NM. 000492.4:c1215-12364 NM. 000492.4:c1215-12364 NM. 000492.4:c1215-1246 NM. 000492.4:c124



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
		NM_000492.4:c.2619+2T>A, NM_000492.4:c.2620-26A>G, NM_000492.4:c.2620-2A>G, NM_000492.4:c.2620- 16>C, NM_000492.4:c.2657+12657+2insA, NM_000492.4:c.2657+5G>A, NM_000492.4:c.2658-2A>G, NM_000492.4:c.2658-16>C, NM_000492.4:c.2658-16>T, NM_000492.4:c.2758C>T, NM_000492.4:c.2658-2687insT, NM_000492.4:c.27050-7A, NM_000492.4:c.2735C>A, NM_000492.4:c.2765, 2687insT, NM_000492.4:c.2738A>G, NM_000492.4:c.2735C>A, NM_000492.4:c.2765, 2687insT, NM_000492.4:c.2738A>G, NM_000492.4:c.2735C>A, NM_000492.4:c.2757C>G, NM_000492.4:c.2738A>G, NM_000492.4:c.2739T>A, NM_000492.4:c.2757C>G, NM_000492.4:c.2735C>A, NM_000492.4:c.2757C>G, NM_000492.4:c.2755C>T, NM_000492.4:c.275_2776deITT, NM_000492.4:c.27521211insG, NM_000492.4:c.2755C>T, NM_000492.4:c.278_2240T, NM_000492.4:c.2825ideIT, NM_000492.4:c.2835C>T, NM_00492.4:c.28226dTT, NM_000492.4:c.2851deIA, NM_000492.4:c.2857>C, NM_000492.4:c.28566>C, NM_000492.4:c.2851deIA, NM_000492.4:c.2857 <c, nm_000492.4:c.28566="">C, NM_000492.4:c.2851deIA, NM_000492.4:c.2905<c, nm_000492.4:c.2809-24700492.4:c.2800492.4:c.2800492.4:c.2800492.4:c.2800492.4:c.2800492.4:c.28566="">C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.2866>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.28956>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.28056>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.28560>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.28056>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.2905-5, NM_00492.4:c.28506>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.28560>C, NM_000492.4:c.285756deIA, NM_000492.4:c.2905-5, NM_000492.4:c.2905-5, NM_00492.4:c.2905-5, NM_00492.4:c.290</c,></c,>
		NM_000492.4:: 2932A=T, NM_000492.4:: 2936A=C, NM_000492.4:: 2936A=T, NM_000492.4:: 2937A NM_000492.4:: 2945_2946deTT, NM_000492.4:: 2967_2958insA, NM_000492.4:: 2988-116=T, NM_000492.4:: 2988-105-C, NM_000492.4:: 2984_2985insC, NM_000492.4:: 2988-105-T, NM_000492.4:: 2988-105-A, NM_000492.4:: 2988-105-C, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-105-C, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2989-2A>T, NM_000492.4:: 2997-2000-2000-2000-2000-2000-2000-2000-
		 NM_000492.4::3154T>G, NM_000492.4::31616/LAN, NM_000492.4::3106CG, NM_000492.4::3176T>G, NM_000492.4::3154T>G, NM_000492.4::3181G>C, NM_000492.4::3183Hin5CTATG, NM_000492.4::3186S¬A, NM_000492.4::3181G>C, NM_000492.4::31984in5CTATG, NM_000492.4::3186S¬A, NM_000492.4::3199G>A, NM_000492.4::3100C>T, NM_000492.4::3196C>T, NM_000492.4::31755A, NM_000492.4::3209G>A, NM_000492.4::3200C>T, NM_000492.4::3196C>T, NM_000492.4::31755A, NM_000492.4::3209G>A, NM_000492.4::3201C>T, NM_000492.4::3196C>T, NM_000492.4::3215321Gin5T, NM_000492.4::3220T>A, NM_000492.4::3226A>G, NM_000492.4::3261_321Gin5T, NM_000492.4::3220T>A, NM_000492.4::3226A NM_000492.4::326C>T, NM_000492.4::3220T>A, NM_000492.4::3226A NM_000492.4::326C>A, NM_000492.4::3220T>A, NM_000492.4::325AA>G, NM_000492.4::326C>A, NM_000492.4::3220T>A, NM_000492.4::325AA>G, NM_000492.4::3276C>A, NM_000492.4::32205C>A, NM_000492.4::325AA>G, NM_000492.4::3276C>A, NM_000492.4::3223CA NM_000492.4::3226C> NM_000492.4::3276C>A, NM_000492.4::3230A> NM_000492.4::3276C>, NM_000492.4::3293deIG, NM_000492.4::3287A> NM_000492.4::3292A> NM_000492.4::3327C> NM_000492.4::33203C> NM_000492.4::33203C> NM_000492.4::33203C> NM_000492.4::33203C> NM_000492.4::33204C> NM_000492.4::33204C> NM_000492.4::33204C NM_000492.4::33204C> NM_000492.4::33204
		NM_000492.4:: 3367-27-C, NM_000492.4:: 3368-2A-G, NM_000492.4:: 3368-2A-T, NM_000492.4:: 3368- 1G>A, NM_000492.4:: 3380G>A, NM_000492.4:: 3382A-T, NM_000492.4:: 3490A-G, NM_000492.4:: 3432G-A, NM_000492.4:: 3436-T, NM_000492.4:: 34346>A, NM_000492.4:: 3435G>A, NM_000492.4:: 3436-1, 3468-2A-T, NM_000492.4:: 34364>A, NM_000492.4:: 3468-1D>A, NM_000492.4:: 3468-1A-T, SM_00492.4:: 3468-2A-T, NM_000492.4:: 3468-1D>A, NM_000492.4:: 3468-1A-T, SM_00492.4:: 3468-2A-T, NM_000492.4:: 3469-2A>G, NM_000492.4:: 3468-1A-T, SM_00492.4:: 3468-2A-T, NM_000492.4:: 3469-2A>G, NM_000492.4:: 3468-2A-T, NM_000492.4:: 3469-2A-T, NM_000492.4:: 3469-2A>G, NM_000492.4:: 3484-2T, NM_000492.4:: 3476-2T, NM_000492.4:: 3469-2A>G, NM_000492.4:: 3484-2T, NM_000492.4:: 3485-2T, NM_000492.4:: 3495-24664G, NM_000492.4:: 3484-2T, NM_000492.4:: 3485-2T, NM_000492.4:: 3495-24664G, NM_000492.4:: 3484-2T, NM_000492.4:: 33526464A, NM_000492.4:: 3345-336646G, NM_000492.4:: 3384642, NM_000492.4:: 35336464, AAC, NM_000492.4:: 3536-37, NM_000492.4:: 35336464, NM_000492.4:: 3545065, NM_000492.4:: 3556-2T, NM_000492.4:: 3569_357040-1T, NM_000492.4:: 3586-2G, NM_000492.4:: 3566-2T, NM_000492.4:: 3569_357040-1T, NM_000492.4:: 3567-2G, NM_000492.4:: 3566-2T, NM_000492.4:: 3569_357040-1T, NM_000492.4:: 3567-2G, NM_000492.4:: 3561-257, NM_000492.4:: 3569_357040-1T, NM_000492.4:: 3567-2G, NM_000492.4:: 3561-257, NM_000492.4:: 3569_357040-1T, NM_000492.4:: 3567-2G, NM_000492.4:: 3561-257, NM_000492.4:: 3560_35704, NM_000492.4:: 3560-257, NM_000492.4:: 3561-35704, NM_000492.4:: 3560-256, NM_000492.4:: 3561-257, NM_000492.4:: 3561-35704, NM_000492.4:: 3560-256, NM_000492.4:: 3561-257, NM_000492.4:: 3560-257, NM_000492.4:: 3560-257, NM_000492.4:: 3561-257, NM_0
		NM_000492.4::.3617C-A, NM_000492.4::.3618_3619deiAG, NM_000492.4::.3617C-G, NM_000492.4::.3619deiG, NM_000492.4::.3667_3658insA, NM_000492.4::.3659deiC, NM_000492.4::.3659C-T, NM_000492.4::.3712C-T, NM_000492.4::.3713C-A, NM_000492.4::.3718- NM_000492.4::.3714-AG-S, MM_000492.4::.3712C-T, NM_000492.4::.3717-40A-G, NM_000492.4::.3718-2477C-T, NM_000492.4::.3718-3T-G, NM_000492.4::.3718-1G-A, NM_000492.4::.3718-2477C-T, NM_000492.4::.3718-3T-G, NM_000492.4::.3718-1G-A, NM_000492.4::.3719-G, NM_000492.4::.3728T-A, NM_000492.4::.3718-1G-A, NM_000492.4::.3745G-A, MM_000492.4::.3728T-A, NM_000492.4::.3718-1G-A, NM_000492.4::.3745G-A, MM_000492.4::.3746G-A, NM_000492.4::.3756G-A, NM_000492.4::.3764G-C, NM_000492.4::.3765C, NM_000492.4::.3746G-A, NM_000492.4::.3756G-A, NM_000492.4::.3764G-C, NM_000492.4::.3761T-C, NM_000492.4::.3746G-A, NM_000492.4::.3756G-A, NM_000492.4::.3764G-C, NM_000492.4::.3764T-C, NM_000492.4::.3746G-A, NM_000492.4::.3766G-A, NM_000492.4::.3764C-T, NM_000492.4::.3764T-C, NM_000492.4::.3786C-A, NM_000492.4::.3766C-T, NM_000492.4::.3764T-C, NM_000492.4::.3876C-A, NM_000492.4::.3766C-T, NM_000492.4::.3764T-C, NM_000492.4::.3886T-C, NM_000492.4::.3766T-C, NM_000492.4::.3812_38156ETT, NM_000492.4::.3822G-A, NM_000492.4::.3884E1A, NM_000492.4::.3812_38356ETT, NM_000492.4::.3824C-T, NM_000492.4::.3884E1-T, NM_000492.4::.3844T-G,
		NN_000492.4:c.3846G>A, NM_000492.4:c.3848G>T, NM_000492.4:c.3849_3850insAA, NM_000492.4:c.3854del(C, NM_000492.4:c.3857T>C, NM_000492.4:c.3863C>A, M_000492.4:c.38731C>T, NM_000492.4:c.3873G>C, NM_000492.4:c.3874-AA, NM_000492.4:c.3874-1G>A, NM_000492.4:c.387342T>C, NM_000492.4:c.3874-AA>G, NM_000492.4:c.3874-1G>A, NM_000492.4:c.3873481A, NM_000492.4:c.3873.3884in5T, NM_000492.4:c.3873, NM_000492.4:c.3883_384in5G, NM_000492.4:c.3873_3884in5T, NM_000492.4:c.3893, NM_000492.4:c.3887_3895, NM_000492.4:c.3902_3003in5A, NM_000492.4:c.3890_3891in5T, NM_000492.4:c.3897_3898in5T, NM_000492.4:c.3902_3903in5A, NM_000492.4:c.3903delA, NM_000492.4:c.3907A>C, NM_000492.4:c.3902_3003in5A, NM_000492.4:c.3903delA, NM_000492.4:c.3907A>C, NM_000492.4:c.3902 C, NM_000492.4:c.3925CT, NM_000492.4:c.3925A, NM_000492.4:c.3937D>T, NM_000492.4:c.3963+16>A, NM_000492.4:c.3957_3958in5AGG, NM_000492.4:c.3963+16>A, NM_000492.4:c.3963+16>C, NM_000492.4:c.3957_3958in5AGG, NM_000492.4:c.3963+16>A, NM_000492.4:c.3954+15>C, NM_000492.4:c.3954+15>C
		16>A, NM_000492.4:c.3971T>C, NM_000492.4:c.3976delT, NM_000492.4:c.3895G>C, NM_000492.4:c.3987_3988delAC, NM_000492.4:c.3986C>T, NM_000492.4:c.3997delG, NM_000492.4:c.3997G>T, NM_000492.4:c.4003C>T, NM_000492.4:c.404T>C, NM_000492.4:c.4035_4021a5GGG, NM_000492.4:c.4024delG, NM_000492.4:c.4034_4035insCCTA, NM_000492.4:c.4035_4021delCCTAAGC, NM_000492.4:c.4037_4038insA, NM_000492.4:c.4040_4014delGC, NM_000492.4:c.4041delCCTAAGC, NM_000492.4:c.4037_4038insA, NM_000492.4:c.405GoT, NM_000492.4:c.4041delC, NM_000492.4:c.4057delT, NM_000492.4:c.4056GT, NM_000492.4:c.4077_4080delTGTTinsAA, NM_000492.4:c.407delG, NM_000492.4:c.4085_4086insT,



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE DISEASE NAME		VAR NAME
		NM_000492.4:c.4111G>T, NM_000492.4:c.4124A>C, NM_000492.4:c.4126_4130delTTGGA, NM_000492.4:c.4136+1G>A, NM_000492.4:c.4130delC, NM_000492.4:c.4140elA, NM_000492.4:c.41417>C, NM_000492.4:c.4144C>T, NM_000492.4:c.4143C>G, NM_000492.4:c.4144_4145insA, NM_000492.4:c.4144C>T, NM_000492.4:c.4169elA, NM_000492.4:c.4168C>T, NM_000492.4:c.4144C>T, NM_000492.4:c.4169elA, NM_000492.4:c.4168C>T, NM_000492.4:c.4204_201insG, NM_000492.4:c.4201G>T, NM_000492.4:c.4219delG, NM_000492.4:c.4204_201insG, NM_000492.4:c.4201G>T, NM_000492.4:c.4242+1G>T, NM_000492.4:c.4242+T>C, NM_000492.4:c.4242+1G>A, NM_000492.4:c.4242+1G>T, NM_000492.4:c.4242+T>C, NM_000492.4:c.425G>A, NM_000492.4:c.4252delG, NM_000492.4:c.4242+T>C, NM_000492.4:c.4250delA, NM_000492.4:c.4252delG, NM_000492.4:c.426_429TinSC, NM_000492.4:c.4250delA, NM_000492.4:c.4252delG, NM_000492.4:c.426_429TinSC, NM_000492.4:c.427G>C, S, MM_000492.4:c.4236D <t, NM_000492.4:c.4337delG, NM_000492.4:c.4275C>A, NM_000492.4:c.4236D<t, NM_000492.4:c.4337delG, NM_000492.4:c.4350delA, NM_000492.4:c.4336>A, NM_000492.4:c.4337delG, NM_000492.4:c.4357C+T, NM_000492.4:c.426C>T, NM_000492.4:c.1204A, NM_000492.4:c.1210-35_1210-34insTGTGTG, NM_000492.4:c.1210-17_1210-13delGTGTGinsT, NM_000492.4:c.1210-11delTinsGTGTGTG</t, </t,
CLN3	Neuronal ceroid-lipofu	ISCINOSIS NM_001042432.2:c.1272delG, NM_001042432.2:c.1210C>A, NM_001042432.2:c.883G>A, NM_001042432.2:c.622dupT, NM_001042432.2:c.597C>A
CLN5	Ceroid lipofuscinosis, n	NM_006493.4:c.188G>A, NM_006493.4:c.188G>C, NM_006493.4:c.230G>A, NM_006493.4:c.286C>T, NM_006493.4:c.377T>G, NM_006493.4:c.377_378insA, NM_006493.4:c.418C>T, NM_006493.4:c.428A>G, NM_006493.4:c.46T>C, NM_006493.4:c.482C>T, NM_006493.4:c.486C>T, NM_006493.4:c.472T>C, NM_006493.4:c.473C>C, NM_006493.4:c.482C>T, NM_006493.4:c.486C>T, NM_006493.4:c.472T>C, NM_006493.4:c.775_776delaT, NM_006493.4:c.803_818delaTCTGGGAAATGAAAC, NM_006493.4:c.879C>A
CLN6	Ceroid Lipofuscinosis, N 6	Neuronal, NM_017882.3:c.663C>6, NM_017882.3:c.307C>T, NM_017882.3:c.214G>T, NM_017882.3:c.214G>C, NM_017882.3:c.200T>C, NM_017882.3:c.139C>T
CLN8	Ceroid Lipofuscinosis, N 8 (a.ka. Northern Epile	
CLRN1	Usher syndrome, type	3A NM_174878.3:c.633dupT, NM_174878.3:c.433+1061A>T, NM_174878.3:c.189C>A, NM_174878.3:c.144T>G, NM_174878.3:c.118T>G, NM_174878.3:c.92C>T
CNGB3	Achromatopsia 3/Macu degeneration, juvenile	
COL4A3	Alport syndrome	NM_000091.5:c.343delG, NM_000091.5:c.346C>A, NM_000091.5:c.898G>A, NM_000091.5:c.2083G>A, NM_000091.5:c.2110delC, NM_000091.5:c.2954G>T, NM_000091.5:c.4411_4415delTTTTC, NM_000091.5:c.4421T>C, NM_000091.5:c.4571C>G, NM_000091.5:c.5002_*66elAAAAGACACTGAAGCTAA
COL4A4	Alport Syndrome, COL4 Related	4A4- NM_000092.5:c.4923C>A, NM_000092.5:c.4129C>T, NM_000092.5:c.3713C>A, NM_000092.5:c.3601G>A, NM_000092.5:c.2312delG, NM_000092.5:c.71+1G>A
COL7A1	Dystrophic Epidermoly Bullosa, COL7A1-Relate	ed NM_00094.4:c.7300-1G>C, NM_00094.4:c.7912G>T, NM_00094.4:c.7440+4delC, NM_00094.4:c.7411C>T NM_00094.4:c.7345-1G>A, NM_00094.4:c.6346G>A, NM_00094.4:c.6327dupC, NM_00094.4:c.6752C-A, NM_00094.4:c.676G>T, NM_00094.4:c.67116>T, NM_00094.4:c.6327dupC, NM_00094.4:c.6325C-T, NM_00094.4:c.6436C>T, NM_00094.4:c.5027C-T, NM_00094.4:c.5321-1G>A, NM_00094.4:c.5321-1G>A, NM_00094.4:c.5436C>T, NM_00094.4:c.5327C-T, NM_00094.4:c.5327C-T, NM_00094.4:c.5321-1G>A, NM_00094.4:c.4343G>C, NM_00094.4:c.4337C-T, NM_00094.4:c.3325-T, NM_00094.4:c.4336C>T, NM_00094.4:c.4331-1G>T, NM_00094.4:c.3389C>T, NM_00094.4:c.42471dupG, NM_00094.4:c.1907G>T, NM_00094.4:c.4332-A, NM_00094.4:c.3827delG, NM_00094.4:c.766C>T, NM_00094.4:c.1907G>T, NM_00094.4:c.4332C>A, NM_00094.4:c.336C>G, NM_000094.4:c.238C>T
CPS1	Carbamoylphosphate s I deficiency	Synthetase NM_001875.5:c.697C>T, NM_001875.5:c.1631C>T, NM_001875.5:c.1912C>T, NM_001875.5:c.3555delA
CPT1A	Carnitine palmitoyltran deficiency, hepatic, typ	De IA NM_001876.4:c.335_336delCC, NM_001876.4:c.298C>T, NM_001876.4:c.281+1G>Ä, NM_001876.4:c.222C>A
СРТ2	Carnitine palmitoyltran deficiency, hepatic, typ infantile,lethal neonath	De II, NM_000098.3:c.638A>G, NM_000098.3:c.680C>T, NM_000098.3:c.723_724delAC, NM_000098.3:c.886C>T, NM_000098.3:c.1238_1239delAG, NM_000098.3:c.1237C>T,



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
CRB1	Leber congenital amau	MM_201253.3:c.484G>A, NM_201253.3:c.493_501delGATGGAATT, NM_201253.3:c.610_616delGAAATAG, NM_201253.3:c.936T>G, NM_201253.3:c.29290C>T, NM_201253.3:c.2401A>T, NM_201253.3:c.246G>T, NM_201253.3:c.2863T>A, NM_201253.3:c.2843A>T, NM_201253.3:c.2843A>T, NM_201253.3:c.2845T>A, NM_201253.3:c.2843A>T, NM_201253.3:c.2812T>C, NM_201253.3:c.353_3054insTTATA, NM_201253.3:c.3094G>A, NM_201253.3:c.3122T>C, NM_201253.3:c.3997C, NM_201253.3:c.3299T>G, NM_201253.3:c.3383delT, NM_201253.3:c.3419T>A, NM_201253.3:c.3997G>T
CTNS	Cystinosis, nephropath	NM_004937.3:c.589G>A, NM_004937.3:c.645_646insA, NM_004937.3:c.853-3C>G, NM_004937.3:c.1015G>A
CTSD	Ceroid Lipofuscinosis, I 10 (CLN10 Disease)	leuronal, NM_001909.5:c.1149G>C, NM_001909.5:c.685T>A
СТЅК	Pycnodysostosis	NM_000396.4:c.926T>C, NM_000396.4:c.721C>T, NM_000396.4:c.436G>C, NM_000396.4:c.236G>A, NM_000396.4:c.154A>T
CYP21A2	Adrenal hyperplasia, congenital/Hyperandro nonclassic type due to hydroxylase deficiency	-
DBT	Maple syrup urine dise	ase, type NM_001918.5:c.1281+1G>A, NM_001918.5:c.939G>C, NM_001918.5:c.901C>T, NM_001918.5:c.871C>T, NM_001918.5:c.827T>G, NM_001918.5:c.772+1G>A, NM_001918.5:c.670G>T, NM_001918.5:c.581C>G, NM_001918.5:c.294C>G, NM_001918.5:c.272_275delCAGT, NM_001918.5:c.126T>G
DCLRE1C	Omenn syndrome/Sev combined immunodefi Athabascan type	
DDB2	Xeroderma Pigmentos E	Im Group NM_000107.3:c.730A>G, NM_000107.3:c.818G>A, NM_000107.3:c.919G>T, NM_000107.3:c.937C>T
DHCR7	Smith-Lemli-Opitz sync	NM_001360.3:c.1342G>A, NM_001360.3:c.1337G>A, NM_001360.3:c.1228G>A, NM_001360.3:c.1210C>T, NM_001360.3:c.1055G>A, NM_001360.3:c.1054C>T, NM_001360.3:c.1031C>A, NM_001360.3:c.976C>T, NM_001360.3:c.961-G>C, NM_001360.3:c.1054C>T, NM_001360.3:c.904T>C, NM_001360.3:c.96C>T, NM_001360.3:c.941G>A, NM_001360.3:c.934>A, NM_001360.3:c.904T>C, NM_001360.3:c.744C>T, NM_001360.3:c.941G>A, NM_001360.3:c.725G>A, NM_001360.3:c.934>C, NM_001360.3:c.744C>T, NM_001360.3:c.506C>T, NM_001360.3:c.725G>A, NM_001360.3:c.435G>A, NM_001360.3:c.632C>T, NM_001360.3:c.556C>T, NM_001360.3:c.729C>T, NM_001360.3:c.453G>A, NM_001360.3:c.453G>A, NM_001360.3:c.356A>T, NM_001360.3:c.292C>T, NM_001360.3:c.278C>T, NM_001360.3:c.151C>T, NM_001360.3:c.1A>G
DHDDS	Retinitis pigmentosa 5	NM_205861.3:c.124A>G, NM_205861.3:c.328deIA, NM_205861.3:c.995C>G
DKC1	Dyskeratosis congenita	, X-Linked NM_001363.5:c.91C>A, NM_001363.5:c.91C>G, NM_001363.5:c.194G>C, NM_001363.5:c.196A>G, NM_001363.5:c.200C>T, NM_001363.5:c.204C>A, NM_001363.5:c.214_215delCTinsTA, NM_001363.5:c.838A>C
DLD	Dihydrolipoamide dehydrogenase deficie	NM_000108.5:c.105_106insA, NM_000108.5:c.913_923delACTTGTGATGT, NM_000108.5:c.1483A>G
DMD	Duchenne muscular dy	Strophy NM_004006.3:c.10774delA, NM_004006.3:c.10454delT, NM_004006.3:c.10453_10454delCT, NM_004006.3:c.1047_10448delTC, NM_004006.3:c.10141CT, NM_004006.3:c.10086+16>A, NM_004006.3:c.938105 NM_004006.3:c.938205 NM_004006.3:c.988205 NM_004006.3:c.982657, NM_004006.3:c.9826267, NM_004006.3:c.9382056, NM_004006.3:c.9850-2A>G, NM_004006.3:c.985627, NM_004006.3:c.95864-16>A, NM_004006.3:c.938056, NM_004006.3:c.93727, NM_004006.3:c.93614-16>A, NM_004006.3:c.938056, NM_004006.3:c.93727, NM_004006.3:c.93614-16>A, NM_004006.3:c.934627, NM_004006.3:c.93727, NM_004006.3:c.9364-16>A, NM_004006.3:c.84427, NM_004006.3:c.860827, NM_004006.3:c.865627, NM_004006.3:c.844237, NM_004006.3:c.860827, NM_004006.3:c.835864-7, NM_004006.3:c.844237, NM_004006.3:c.78842-7, NM_004006.3:c.86586417A, NM_004006.3:c.76836>A, NM_004006.3:c.78842-7, NM_004006.3:c.69366417A, NM_004006.3:c.6936461C, NM_004006.3:c.6763-2A>G, NM_004006.3:c.69366417A, NM_004006.3:c.69344017, NM_004006.3:c.6763-2A>G, NM_004006.3:c.69366417A, NM_004006.3:c.693461C, NM_004006.3:c.67632-2A>G, NM_004006.3:c.69366417A, NM_004006.3:c.6932612, NM_004006.3:c.67632-2A>G, NM_004006.3:c.693267, NM_004006.3:c.6932647, NM_004006.3:c.6932612, NM_004006.3:c.67632-2A>G, NM_004006.3:c.693267, NM_004006.3:c.6932647, NM_004006.3:c.69326412, NM_004006.3:c.6332461, NM_004006.3:c.6932647, NM_004006.3:c.69326412, NM_004006.3:c.6332461, NM_004006.3:c.6932647, NM_004006.3:c.6325457, NM_004006.3:c.6332461, NM_004006.3:c.6932647, NM_004006.3:c.6325457, NM_004006.3:c.6332461, NM_004006.3:c.6932657, NM_004006.3:c.593267, NM_004006.3:c.5352657, NM_004006.3:c.530757, NM_004006.3:c.5593267, NM_004006.3:c.593267, NM_004006.3:c.535357, NM_004006.3:c.538727, NM_004006.3:c.5593267, NM_004006.3:c.4392642, NM_004006.3:c.537557, NM_004006.3:c.538727, NM_004006.3:c.5393267, NM_004006.3:c.4395267, NM_004006.3:c.337267, NM_004006.3:c.53872757, NM_004006.3:c.5397267, NM_004006.3:c.4395267, NM_004006.



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
		NM_004006.3:c.2804-2A>T, NM_004006.3:c.2803+1G>T, NM_004006.3:c.2803+1G>A, NM_004006.3:c.25236CT, NM_004006.3:c.2755A>T, NM_004006.3:c.2560C-T, NM_004006.3:c.2574GelT, NM_004006.3:c.25236CT, NM_004006.3:c.2484T>G, NM_004006.3:c.2484T>G, NM_004006.3:c.2479delG, NM_004006.3:c.2239-229742274CTAT, NM_004006.3:c.2382+2482T>G, NM_004006.3:c.2332C>T, NM_004006.3:c.22374C2T, NM_004006.3:c.2380+1G>C, NM_004006.3:c.12332C>T, NM_004006.3:c.2332C>T, NM_004006.3:c.22374C2T, NM_004006.3:c.2382+2285delGAAAA, NM_004006.3:c.2332C>T, NM_004006.3:c.2337C>T, NM_004006.3:c.12352elG, NM_004006.3:c.1334delA, NM_004006.3:c.15291250deTC, NM_004006.3:c.1332-65T, NM_004006.3:c.1304delA, NM_004006.3:c.1238C+D, NM_004006.3:c.1332-9A>G, NM_004006.3:c.1304delA, NM_004006.3:c.1232156C>T, NM_004006.3:c.1332-9A>G, NM_004006.3:c.1306delpG, NM_004006.3:c.1232155C>T, NM_004006.3:c.1332-9A>G, NM_004006.3:c.1304delA, NM_004006.3:c.1235C+T, NM_004006.3:c.132567L, MM_004006.3:c.130704elC, NM_004006.3:c.10486>T, NM_004006.3:c.10326>T, NM_004006.3:c.1322-9A>G, NM_004006.3:c.23024C+T, NM_004006.3:c.10326>T, NM_004006.3:c.1322-9A>G, NM_004006.3:c.20040C, NM_00406.3:c.13072+T, NM_004006.3:c.1322-9A>G, NM_004006.3:c.20040C, NM_00406.3:c.13072+T, NM_00406.3:c.1322-9A>G, NM_004006.3:c.20040C, NM_004006.3:c.137A>T, NM_00406.3:c.1322-9A>G, NM_004006.3:c.20040C, NM_004006.3:c.137A>T, NM_004006.3:c.1322-9A>G, NM_004006.3:c.20040C, NM_004006.3:c.137A>T, NM_004006.3:c.1322-7, NM_004006.3:c.20040C, NM_004006.3:c.20040C, NM_004006.3:c.137A>T, NM_004006.3:c.132-125C
DPYD	Dihydropyrimidine Dehydrogenase Deficiency	NM_000110.4:c.1905+1G>A, NM_000110.4:c.1679T>G, NM_000110.4:c.1109_1110delTA, NM_000110.4:c.775A>G, NM_000110.4:c.703C>T, NM_000110.4:c.299_302delTCAT, NM_000110.4:c.257C>T
DYSF	Muscular dystrophy, limb- type 2B	girdle, MM_001130987.2:::2392.204deITGinsAT, NM_001130987.2::289A>C, NM_001130987.2:::394_395deICC, NM_001130987.2::087C5T, NM_001130987.2::C591C5C, NM_001130987.2::797C5A, NM_001130987.2::0825C5T, NM_001130987.2::591C5A, NM_001130987.2::191C5A, NM_001130987.2::0825C5T, NM_001130987.2::191C5A, NM_001130987.2::1216C5C, NM_001130987.2::101C5C, NM_001130987.2::191C5A, NM_001130987.2::11465C, NM_001130987.2::1464CA, NM_001130987.2::1497.1483InsA, NM_001130987.2::1494-2A>G, NM_001130987.2::1674deIA, NM_001130987.2::1497.1483InsA, NM_001130987.2::191C5C, NM_001130987.2::1674deIA, NM_00130987.2::1692+2T>A, NM_001130987.2::191C5C, NM_001130987.2::1677deIA, NM_00130987.2::16242T>A, NM_001130987.2::191C5C, NM_001130987.2::1677deIA, NM_00130987.2::3051C5T, NM_001130987.2::191C5C, NM_001130987.2::175C5T, NM_001130987.2::3051C5T, NM_001130987.2::305A>G, NM_001130987.2::3175C5T, NM_001130987.2::3184C5T, NM_001130987.2::305A>G, NM_001130987.2::3175C5T, NM_001130987.2::3184C5T, NM_001130987.2::305A>G, NM_001130987.2::3229.2A>T, NM_001130987.2::3212542 NM_001130987.2::3229.2A>T, NM_001130987.2::3184C5T, NM_001130987.2::305A>G, NM_001130987.2::3239.3499deITGinsAA, NM_001130987.2::305A>G, NM_001130987.2::3239.345T, NM_001130987.2::3184C5T, NM_001130987.2::305A>G, NM_001130987.2::3239.345T, NM_001130987.2::3165A>C, NM_001130987.2::305A>G, NM_001130987.2::3259.345T, NM_001130987.2::316A>C, NM_001130987.2::305A>G, NM_001130987.2::3259.345T, NM_001130987.2::316A>C, NM_001130987.2::305A>G, NM_001130987.2::3259.345T, NM_001130987.2::316A>C, NM_001130987.2::305A>G, NM_001130987.2::3259.345T, NM_001130987.2::316A>C, NM_001130987.2::305A>C, NM_001130987.2::3557.445T, NM_001130987.2::316A>C, NM_001130987.2::305A>C, NM_001130987.2::3557.445T, NM_001130987.2::3193A>C, NM_001130987.2::4358>C, NM_001130987.2::3557.445T, NM_001130987.2::3193A>C, NM_001130987.2::5542>C, NM_001130987.2::3193A>C, NM_001130987.2::5542>C, NM_001130987.2::5194>C, NM_001130987.2::5542>A, NM_001130987.2::5104>C, NM_001130987.2::5566>A, NM_0
EDA	Ectodermal dysplasia 1, hypohidrotic, X-linked	NM_001399.5rc.181T>C, NM_001399.5rc.183C>G, NM_001399.5rc.187G>A, NM_001399.5rc.206G>T, NM_001399.5rc.463C>T, NM_001399.5rc.466C>T, NM_001399.5rc.467G>A, NM_001399.5rc.573_574insT, NM_001399.5rc.671G>C, NM_001399.5rc.826C>T, NM_001399.5rc.1045G>A
EIF2AK3	Wolcott-Rallison Syndrom	e NM_004836.7:c.1763G>A, NM_004836.7:c.994G>T
EMD	Emery-Dreifuss Muscular Dystrophy 1, X-Linked	NM_000117.3:c.547C>A, NM_000117.3:c.630_634delCCGTG
ERCC2	Xeroderma Pigmentosum D	Group NM_000400.4:c.2230_2233dupCTAG, NM_000400.4:c.2176C>T, NM_000400.4:c.2047C>T, NM_000400.4:c.2047C>T, NM_000400.4:c.21762T>T, NM_000400.4:c.217192T>T, NM_000400.4:c.2
ERCC3	Xeroderma Pigmentosum B	Group NM_000122.2:c.1858delG, NM_000122.2:c.1757_1758delAG, NM_000122.2:c.1757delA, NM_000122.2:c.1633C>T, NM_000122.2:c.1273C>T, NM_000122.2:c.296T>C
ERCC4	Xeroderma Pigmentosum F	Group NM_005236.3:c.2T>C, NM_005236.3:c.49G>T, NM_005236.3:c.538_539delAG, NM_005236.3:c.706T>C, NM_005236.3:c.1461_1462InsA, NM_005236.3:c.2280_2283delGTTT, NM_005236.3:c.2395C>T
ERCC5	Xeroderma pigmentosum, G/Cockayne syndrome	NM_000123.4:c.2143_2144insA, NM_000123.4:c.2375C>T, NM_000123.4:c.2573T>C, NM_000123.4:c.250G>A, NM_000123.4:c.2743deIA
ERCC6	Cockayne syndrome	NM_000124.4:c.3862C>T, NM_000124.4:c.3591_3592dupGA, NM_000124.4:c.3284C>G, NM_000124.4:c.2587C>T, NM_000124.4:c.2203C>T, NM_000124.4:c.2047C>T, NM_000124.4:c.1550G>A, NM_000124.4:c.1357C>T, NM_000124.4:c.422+1G>A, NM_000124.4:c.207dupG, NM_000124.4:c.48_49delCT
ERCC8	Cockayne, type A	NM_000082.4:c.966C>A, NM_000082.4:c.618-1G>A, NM_000082.4:c.613G>C, NM_000082.4:c.593_594dupAT, NM_000082.4:c.37G>T
ESCO2	Roberts Syndrome	NM_001017420.3:c.291_292insGA, NM_001017420.3:c.306_307deIAA, NM_001017420.3:c.505C>T, NM_001017420.3:c.604C>T, NM_001017420.3:c.874_877deIGACA, NM_001017420.3:c.877_878deIAG, NM_001017420.3:c.1269G>A, NM_001017420.3:c.1596_1597insT, NM_001017420.3:c.1615T>G



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME	
ETFA	Glutaric acidemia IIA	NM_000126.4:c.797C>T, NM_000126.4:c.470T>G	
ETFB	Glutaric Acidemia, Type	2 2B NM_001985.3:c.614_616deIAGA, NM_001985.3:c.491G>A, NM_001985.3:c.490C>T, NM_001985.3:c. NM_001985.3:c.278_279insG, NM_001985.3:c.61C>T, NM_001985.3:c.58-53_58-52insG	382G>A,
ETFDH	Glutaric aciduria type I	C NM_004453.4:c.2T>C, NM_004453.4:c.2305-A, NM_004453.4:c.413T>G, NM_004453.4:c.50865-T, NM_004453.4:c.2456-T, NM_004453.4:c.13670-NM_004453.4:c.1001T>C, NM_004453.4:c.123463 NM_004453.4:c.1351G>C, NM_004453.4:c.1367C>T, NM_004453.4:c.1568_1569delCT, NM_004453.4:c.1773_1774delAT, NM_004453.4:c.1822delG, NM_004453.4:c.1832G>A	Τ,
ETHE1	Ethylmalonic Encephal	Deathy NM_014297.5:c.604dup6, NM_014297.5:c.554756, NM_014297.5:c.48865A, NM_014297.5:c.48865A, NM_014297.5:c.487651 NM_014297.5:c.440_450delACA6CATGGCC, NM_014297.5:c.221dupA	·,
EYS	Retinitis pigmentosa 2	 NM_001142800.2:c:9405T>A, NM_001142800.2:c:9299_9302delCTCA, NM_001142800.2:c:9036delT, NM_001142800.2:c:8834G>A, NM_001142800.2:c:8468_8655delCATGCAGA, NM_001142800.2:c:829_85324UpACAG, NM_001142800.2:c:84056G>T, NM_001142800.2:c:8408dup NM_001142800.2:c:6170delA, NM_001142800.2:c:5175/dupT, NM_001142800.2:c:5928-2A>G, NM_001142800.2:c:5875G>T, NM_001142800.2:c:5757dupT, NM_001142800.2:c:5044G>T, NM_001142800.2:c:5757dupT, NM_001142800.2:c:5044G>T, NM_001142800.2:c:5575dupT, NM_001142800.2:c:5044G>T, NM_001142800.2:c:5575dupT, NM_001142800.2:c:5044G>T, NM_001142800.2:c:5575dupT, NM_001142800.2:c:5044G>T, NM_001142800.2:c:5575dupT, NM_001142800.2:c:402G>T, NM_001142800.2:c:3529C=G, NM_001142800.2:c:2826_2827delAT, NM_001142800.2:c:49C=T, NM_001142800.2:c:4534_863-3inST, NM_001142800.2:c:571dupA, NM_001142800.2:c:49C-T, NM_001142800.2:c:323defT, NM_001142800.2:c:571dupA, NM_001142800.2:c:49C-T, NM_001142800.2:c:324defT, NM_001142800.2:c:392-T, 	А, СТС,
F11	Factor XI deficiency, au recessive	tosomal NM_00128.4::1667-C, NM_000128.4::433G-T, NM_000128.4::438C-A, NM_000128.4::595+3A> NM_00128.4::713A-G, NM_000128.4::6203-T, NM_000128.4::c.901T>C, NM_000128.4::c.1211C>A NM_00128.4::c1613C>T, NM_000128.4::c1693G>A	
F8	Hemophilia A	Intron 22 inversion, NM_000132.4:: 7033_7440detTGCGAGGC, NM_000132.4:: 703G-A, NM_00132.4:: 703G-A, NM_00132.4:: 703G-A, NM_00132.4:: 703G-A, NM_000132.4:: 703G-A, NM_000132.4:: 703G-A, NM_000132.4:: 703G-A, NM_000132.4:: 703G-A, NM_00132.4:: 703G-A, NM_00132.4:: 703G-A, NM_00132.4:: 703G-A, NM_00132.4:: 703G-A, NM_000132.4:: 703G-A, NM_00132.4:: 703G-A, NM_000132.4:: 703G-A, NM_000132.4:: 703G	26> ۲, 26, 26, 26, 26, 26, 27, 27, 20, 20, 20, 20, 20, 20, 20, 20



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE DISEASE NAME		VAR NAME
		NM_000132.4:c.128dupT, NM_000132.4:c.120delC, NM_000132.4:c.98G>A, NM_000132.4:c.97T>G, NM_000132.4:c.88G>A, NM_000132.4:c.86T>G, NM_000132.4:c.77T>C, NM_000132.4:c.73delT, NM_000132.4:c.65G>C, NM_000132.4:c.1A>G
F9	Hemophilia B	NM_000133.4:c.19A>T, NM_000133.4:c.52T>C, NM_000133.4:c.79G>A, NM_000133.4:c.80A>T, NM_000133.4:c.82T>C, NM_000133.4:c.1031T>C, NM_000133.4:c.1136G>A, NM_000133.4:c.1150C>T
FAH	Tyrosinemia, type I	NM_00137.4:c.47A>T, NM_000137.4:c.103G>A, NM_000137.4:c.192G>T, NM_000137.4:c.401C>A, NM_000137.4:c.456G>A, NM_000137.4:c.554-1G>T, NM_000137.4:c.607-6T>G, NM_000137.4:c.707-1G>A, NM_000137.4:c.7205-CT, NM_00137.4:c.737-1G>A, NM_000137.4:c.707-1G>A, NM_000137.4:c.782C>T, NM_00137.4:c.103G>A, NM_000137.4:c.1021C>T, NM_000137.4:c.702-CT, NM_000137.4:c.1022C>T, NM_000137.4:c.1009G>A, NM_000137.4:c.1021C>T, NM_000137.4:c.1027C>T, NM_000137.4:c.1022C>T, NM_000137.4:c.1009G>A, NM_000137.4:c.1020G>T, NM_000137.4:c.1021C>T, NM_000137.4:c.1022C>T, NM_000137.4:c.1009G>T, NM_000137.4:c.1090G>T, NM_000137.4:c.1041A>G
FANCA	Fanconi anemia,	NM_000135.4:c.4130C>G, NM_000135.4:c.3788_3790deITCT, NM_000135.4:c.3763G>T, NM_000135.4:c.3558dupG, NM_000135.4:c.2303T>C, NM_000135.4:c.1115_1118deITTGG,
	complementation grou	
FANCC	Fanconi anemia, complementation grou	NM_000136.3:c.1642C>T, NM_000136.3:c.1487T>G, NM_000136.3:c.1103_1104delTG, NM_000136.3:c.1015delA, NM_000136.3:c.996+1G>T, NM_000136.3:c.416G>A, NM_000136.3:c.67delG, NM_000136.3:c.37C>T
FANCG	Fanconi anemia, complementation grou	DG NM_004629.2:c.1852_1853delAA, NM_004629.2:c.1795_1804delTGGATCCGTC, NM_004629.2:c.1480+1G>C, NM_004629.2:c.1077-2A>G, NM_004629.2:c.307_908dupCT, NM_004629.2:c.637_643delTACCGCC, NM_004629.2:c.510+1G>A, NM_004629.2:c.313G>T
FH	Fumarase Deficiency	NM_000143.4:c.1446_1449delAAAG, NM_000143.4:c.1431_1433dupAAA, NM_000143.4:c.1394A>G, NM_000143.4:c.1293delA, NM_000143.4:c.1255T>C, NM_000143.4:c.1361-6 <c, nm_000143.4:c.1264<br="">NM_000143.4:c.1395<a, nm_000143.4:c.1093a="">G, NM_000143.4:c.1067T>A, NM_000143.4:c.301dupA, NM_000143.4:c.793G>A, NM_000143.4:c.700C>T, NM_000143.4:c.1697C>T, NM_000143.4:c.521C>G, NM_000143.4:c.521C>G, NM_000143.4:c.320A>C, NM_000143.4:c.40dupC</a,></c,>
FKRP	Muscular dystrophy- dystroglycanopathy (lir type C, 5	NM_024301.5:c.160C>T, NM_024301.5:c.235G>A, NM_024301.5:c.1154C>A, NM_024301.5:c.1343C>T, NM_024301.5:c.1387A>G
FKTN	Muscular dystrophy- dystroglycanopathy (cc with brain and eye ano type A, 4	
FMR1	Fragile X syndrome	Premutation allele (CGG)n
G6PC1/ G6PC	Glycogen storage disea Gierke disease)	Se la (von NM_000151.4::c47CsG, NM_000151.4::c113A>T, NM_000151.4::229T>C, NM_000151.4::230+1G>C, NM_000151.4::247C>T, NM_000151.4::247C>T, NM_000151.4::247C>T, NM_000151.4::247C>T, NM_000151.4::247C>T, NM_000151.4::247C>T, NM_000151.4::251C>A, NM_000151.4::250C>A, NM_000151.4::250C>A, NM_000151.4::250C>A, NM_000151.4::250C>A, NM_000151.4::250C>A, NM_000151.4::250C>A, NM_000151.4::250
GAA	Glycogen storage disea (Pompe disease)	NM_000152.5:c.655G>A, NM_000152.5:c.697delA, NM_000152.5:c.710C>T, NM_000152.5:c.767_768insT, NM_000152.5:c.165T NM_000152.5:c.164T NM_000152.5:c.1167A NM_000152.5:c.1645G NM_000152.5:c.1645G NM_000152.5:c.1164C NM_000152.5:c.1164G NM_000152.5:c.1645G NM_000152.5:c.1164G NM_000152.5:c.1164G NM_000152.5:c.1645G NM_000152.5:c.1164G NM_000152.5:c.1164G NM_000152.5:c.1645G NM_000152.5:c.164G NM_000152.5:c.164G NM_000152.5:c.1645G NM_000152.5:c.1646 NM_000152.5:c.1646 NM_000152.5:c.1645G NM_000152.5:c.1646 NM_000152.5:c.1646 NM_000152.5:c.1799G>A, NM_000152.5:c.1642 NM_000152.5:c.1646 NM_000152.5:c.1646 NM_000152.5:c.1936G NM_000152.5:c.1936G NM_000152.5:c.1936G NM_000152.5:c.1936G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2018G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2017G NM_000152.5:c.2512C NM_000152.5:c.25436 NM_000152.5:c.2560C>T NM_000152.5:c.2512C NM_000152.5:c.2543delC NM_000152.5:c.2560C>T </td
GALC	Krabbe disease	NM_000153.4:c.2056T>C, NM_000153.4:c.1964delC, NM_000153.4:c.1814dupA, NM_000153.4:c.1796T>G, NM_000153.4:c.1723_1724InsT, NM_000153.4:c.1700A>C, NM_000153.4:c.1695delT, NM_000153.4:c.1592C>A, NM_000153.4:c.1591C-T, NM_000153.4:c.1586C>T, NM_000153.4:c.1592C NM_000153.4:c.1489-12489-3delTG, NM_000153.4:c.1448_1489-12delTGGT, NM_000153.4:c.1488_14894ETG, NM_000153.4:c.1472delA, NM_000153.4:c.16142T>G, NM_000153.4:c.1153G>T, NM_000153.4:c.1042A c, NM_000153.4:c.658C>T, NM_00015



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
GALT	Galactosemia	NM_000155.4:c.17delC, NM_000155.4:c.41delCinsTT, NM_000155.4:c.17_72insA, NM_000155.4:c.143G>C, NM_000155.4:c.113G>A, NM_000155.4:c.132GeJ, NM_000155.4:c.132GeJ, NM_000155.4:c.132GeJ, NM_000155.4:c.132GeJ, NM_000155.4:c.200G>A, NM_000155.4:c.
GAMT	Guanidinoacetate methyltransferase defi	NM_000156.6:c.590T>C, NM_000156.6:c.506G>A
GBE1	Glycogen storage disea	Se IV NM_000158.4:c.1052+16>A, NM_000158.4:c.1883A>G, NM_000158.4:c.1774G>T, NM_000158.4:c.1604A>G, NM_000158.4:c.1571G>A, NM_000158.4:c.1570C>T, NM_000158.4:c.1543C>T, NM_000158.4:c.986A>G, NM_000158.4:c.986A>C, NM_000158.4:c.771T>A, NM_000158.4:c.466_470del/CGTAT
GCDH	Glutaricaciduria, type I	NM_000159.4:c.74C>A, NM_000159.4:c.271+1G>A, NM_000159.4:c.383G>A, NM_000159.4:c.416C>T, NM_00159.4:c.42G>A, NM_000159.4:c.542A>G, NM_000159.4:c.572T>F, NM_000159.4:c.636-1G>A, NM_000159.4:c.769C>T, NM_00159.4:c.767C>T, NM_000159.4:c.764C>T, NM_000159.4:c.769C>T, NM_000159.4:c.767C>T, NM_000159.4:c.764C>T, NM_000159.4:c.947C>A, NM_000159.4:c.761C>T, NM_000159.4:c.761C>T, NM_000159.4:c.947C>A, NM_000159.4:c.877G>A, NM_000159.4:c.831>C, NM_000159.4:c.914C>T, NM_000159.4:c.947C>A, NM_000159.4:c.1001_1002de14G, NM_000159.4:c.1015A>C, NM_000159.4:c.1186G>C, NM_000159.4:c.1001_50.4:c.193G>A, NM_000159.4:c.1148G>A, NM_000159.4:c.1204C>T, NM_000159.4:c.1242A>C, NM_000159.4:c.1247C>T, NM_000159.4:c.1262C>T
GFM1	Combined Oxidative Phosphorylation Defici	NM_024996.7:c.139C>T, NM_024996.7:c.521A>G, NM_024996.7:c.748C>T, NM_024996.7:c.1294_1297deIACAG, NM_024996.7:c.1528_1529deIAG
GJB2	Deafness, autosomal re	Cessive 1 NM_004004.6:c.5172-S; NM_004004.6:c.5570-T; NM_004004.6:c.5150-C-T; NM_004004.6:c.5165-A; NM_004004.6:c.5500-C-T; NM_004004.6:c.5165-A; NM_004004.6:c.4565-A; NM_004004.6:c.4365-A; NM_004004.6:c.4365-A; NM_004004.6:c.4365-A; NM_004004.6:c.4365-A; NM_004004.6:c.4365-A; NM_004004.6:c.4365-A; NM_004004.6:c.313, 23644-A; NM_004004.6:c.290, NM_004004.6:c.230, 2364-A; NM_004004.6:c.330, 2364-A; NM_004004.6:c.330, 2364-A; NM_004004.6:c.330, 2364-A; NM_004004.6:c.330, 2364-A; NM_004004.6:c.350, 2364-A; NM_004004.6:c.350, 2364-A; NM_004004.6:c.350, 2364-A; NM_004004.6:c.350, 2364-A; NM_004004.6:c.350, 2364-A; NM_004
GJB3	Deafness, autosomal re	Cessive NM_024009.3:c.94C>T, NM_024009.3:c.529T>G, NM_024009.3:c.580G>A
GJB6	Deafness, autosomal re	
GLB1	GM1 gangliosidosis and mucopolysaccharidosis	type IVB NM_000404.4:c.144(5-T, NM_000404.4:c.1370G>A, NM_000404.4:c.1365G>T, NM_000404.4:c.1355dupA, NM_000404.4:c.1325G>A, NM_000404.4:c.1311G>A, NM_000404.4:c.1365G>A, NM_000404.4:c.1310A>T, NM_000404.4:c.1025C>A, NM_000404.4:c.131115A NM_000404.4:c.1325G>A, NM_000404.4:c.131115A NM_000404.4:c.13110A>T, NM_000404.4:c.1051C>T, NM_000404.4:c.131115A NM_000404.4:c.1325G>A, NM_000404.4:c.131115A NM_000404.4:c.1016A>T, NM_000404.4:c.1051C>T, NM_000404.4:c.1016A>T, NM_000404.4:c.1016A>T, NM_000404.4:C.1016A>T, NM_000404.4:c.1016A>T, NM_000404.4:c.142C>A, NM_000404.4:C.1016A>T, NM_000404.4:c.42C>A, NM_000404.4:c.42C>A, NM_000404.4:c.42C>A, NM_000404.4:c.145C>T, NM_000404.4:c.152T>C, NM_000404.4:c.152T>C,
GLDC	Glycine encephalopath related)	NM_000170.3:c.1166C>T, NM_000170.3:c.322G>T
GLE1	Lethal Congenital Cont Syndrome 1	acture NM_001003722.2:c. 898-2A>G, NM_001003722.2:c. 1413deIAG, NM_001003722.2:c. 1807C>T, NM_001003722.2:c. 2051T>C, NM_001003722.2:c. 2067_2070deICTTT
GNE	Inclusion body myopat autosomal recessive	NM_001128227.3:c.1891G-A, NM_001128227.3:c.1820G-A, NM_001128227.3:c.1807G>T, NM_001128227.3:c.1002T>A, NM_001128227.3:c.880C>T, NM_001128227.3:c.830G>A, NM_001128227.3:c.766G>A, NM_001128227.3:c.478C>T
GNPTAB	Mucolipidosis type II a	Id III NM_024312.5:c.3663delG, NM_024312.5:c.3598G>A, NM_024312.5:c.3556C>T, NM_024312.5:c.3562_3561delAG, NM_024312.5:c.3530_3504delTC, NM_024312.5:c.3504_3504delTC, NM_024312.5:c.328delA, NM_024312.5:c.3373C>G, NM_024312.5:c.328delA, NM_024312.5:c.13941C>T, NM_024312.5:c.73941C>T, NM_024312.5:c.739540C>T, NM_024312



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
		NM_024312.5:c.648_651delAGAA, NM_024312.5:c.616_619delACAG, NM_024312.5:c.99delC, NM_024312.5:c.25C>T
GNS	Mucopolysaccharidosis (Sanfilippo D)	Type IIID NM_002076.4:c.1226dupG, NM_002076.4:c.1169deIA, NM_002076.4:c.1168C>T, NM_002076.4:c.1063C>T, NM_002076.
GRHPR	Primary Hyperoxaluria	Type 2 NM_012203.2:c.101delG, NM_012203.2:c.295C>T, NM_012203.2:c.435G>A, NM_012203.2:c.622C>T
GUCY2D	Characterization Leber congenital amau	DSIS 1 NM_000180.4:c.456C>A, NM_000180.4:c.620delC, NM_000180.4:c.1694T>C, NM_000180.4:c.2734_2735delTT, NM_000180.4:c.2945-1delG
GUSB	Mucopolysaccharidosis	Type VII NM_000181.4:c.1881G>T, NM_000181.4:c.1856C>T, NM_000181.4:c.1831C>T, NM_000181.4:c.1730G>T, NM_000181.4:c.1530G>T, NM_000181.4:c.1550G>T, NM_000181.4:c
HADHA	Long-chain 3-hydroxya dehydrogenase (LCHAI deficiency	
HADHB	Trifunctional protein d	iciency NM_000183.3:c.788A>G, NM_000183.3:c.1331G>A, NM_000183.3:c.1364T>G
HBA1/2	Thalassemia, alpha	MED ;SEA ;THAI ; - α3.7 ; - α4.2 ; - α20.5 ;FIL



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
HBB	Thalassemias, beta	 NML 00038 5: C 110, "1144471AAA, NML 00038 5: C 113A-G, NML 00038 5: C 1100 C, NML 000318 5: C 1000 C, NML 000318 5: C 1000 C, NML 000318 5: C 1100 C, NML 000318 5: C 1000 C, NML 000318 5: C 10000 C, NML 000318 5: C 1000 C, NML 000318 5: C 1000 C, NML 00031
HEXA	Tay-Sachs disease	NM_000520.6:c.1537C-T, NM_000520.6:c.1528C-T, NM_000520.6:c.15104C, NM_000520.6:c.151163-A, NM_000520.6:c.15016C-T, NM_000520.6:c.1478C-R, NM_000520.6:c.1494G-A, NM_000520.6:c.1494G-A, NM_000520.6:c.1494G-A, NM_000520.6:c.142G-C, NM_000520.6:c.15151-CG, NM_000520.6:c.1277, 1278ins7A7, NM_000520.6:c.1274, 1277dup7AT, NM_000520.6:c.1277-1278ins7A7, NM_000520.6:c.1272-T, 1277bins7A7, NM_000520.6:c.117C-T, NM_000520.6:c.1276-C, NM_000520.6:c.1276-C, NM_000520.6:c.1176-C, NM_000520.6:c.1915_917del(CTT, NM_000520.6:c.1276-C, NM_000520.6:c.1915_917del(CTT, NM_000520.6:c.1276-C, NM_000520.6:c.805+16>-C, NM_000520.6:c.915_917del(CTT, NM_000520.6:c.614A-G, NM_000520.6:c.805+3A>-G, NM_000520.6:c.915_917del(CTT, NM_000520.6:c.739C-T, NM_000520.6:c.614A-G, NM_000520.6:c.726C-C, NM_000520.6:c.726C-C, NM_000520.6:c.726C-C, NM_000520.6:c.726C-C, NM_000520.6:c.726C-C, NM_000520.6:c.736C-T, NM_000520.6:c.736C-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.5336-T, NM_000520.6:c.536C-A, NM_000520.6:c.53



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
		NM_000520.6:c.77G>A, NM_000520.6:c.2T>C, NM_000520.6:c.1A>T, NM_000520.6:c.1A>G
НЕХВ	Sandhoff disease, infar juvenile, and adult forr	
HFE	Hemochromatosis, Typ	e 1 NM_000410.4:c.18G>C, NM_000410.4:c.193A>T, NM_000410.4:c.252G>A, NM_000410.4:c.277G>C, NM_000410.4:c.314T>C, NM_000410.4:c.29G>A, NM_000410.4:c.989G>T
HGD	Alkaptonuria	NM_000187.4:c.1189-2A>G, NM_000187.4:c.1111dupC, NM_000187.4:c.1102A>G, NM_000187.4:c.899T>G, NM_000187.4:c.873C>A, NM_000187.4:c.808C>A, NM_000187.4:c.688C>T, NM_000187.4:c.674C>A, NM_000187.4:c.481G>A, NM_000187.4:c.489+2T>C, NM_000187.4:c.342+1G>A, NM_000187.4:c.283-4C>T, NM_000187.4:c.283-5delT, NM_000187.4:c.175delA, NM_000187.4:c.172A>T, NM_000187.4:c.140C>T, NM_000187.4:c.16-1G>A
HGSNAT	Mucopolysaccharidosis (Sanfilippo C)/Retinitis pigmentosa 73	type IIIC NM_152419.3:c.493+16>A, NM_152419.3:c.607C>T, NM_152419.3:c.848C>T, NM_152419.3:c.1030C>T, NM_152419.3:c.1250+16>A, NM_152419.3:c.1378-16>A, NM_152419.3:c.1464+16>A, NM_152419.3:c.1501delA, NM_152419.3:c.1553C>T, NM_152419.3:c.1622C>T, NM_152419.3:c.18436>A
HMGCL	HMG-CoA lyase deficie	NM_000191.3:c.835G>A, NM_000191.3:c.698A>G, NM_000191.3:c.505_506delTC, NM_000191.3:c.230delT, NM_000191.3:c.206_207delCT, NM_000191.3:c.122G>A
HPD	Tyrosinemia, type III	NM_002150.3:c.1005C>G, NM_002150.3:c.987delA, NM_002150.3:c.774T>G, NM_002150.3:c.600C>G
HPS1	Hermansky-Pudlak Syn	drome 1 NM_000195.5:c.1996G>T, NM_000195.5:c.1472_1487dupCCAGCAGGGGAGGCCC, NM_000195.5:c.972delC, NM_000195.5:c.398+5G>A, NM_000195.5:c.397G>T
HSD17B4	D-bifunctional protein	deficiency NM_000414.4:c.456>A, NM_000414.4:c.317G>C, NM_000414.4:c.650A>G, NM_000414.4:c.972+1G>T, NM_000414.4:c.1369A>T
HYLS1	Hydrolethalus Syndron	NM_001134793.2:c.632A>G, NM_001134793.2:c.669G>A, NM_001134793.2:c.724C>T
IDS	Mucopolysaccharidosis (Hunter Syndrome)	Type II NM_000202.8:c.1508T>A, NM_000202.8:c.1505G>C, NM_000202.8:c.1466G>C, NM_000202.8:c.1464G>T, NM_000202.8:c.1484GIC, NM_000202.8:c.122C>T, NM_000202.8:c.937C>T, NM_000202.8:c.880-8A>G, NM_000202.8:c.690_691insT, NM_000202.8:c.683C>T, NM_000202.8:c.596_599deIAACA, NM_000202.8:c.597EA, NM_000202.8:c.587T>C, NM_000202.8:c.596_599deIAACA, NM_000202.8:c.597EA, NM_000202.8:c.587T>C, NM_000202.8:c.587EA, NM_000202.8:c.288EA, NM_000202.8:c.288EA, NM_000202.8:c.288EA, NM_000202.8:c.288EA, NM_000202.8:c.208EA, NM_
IKBAP/ ELP1	Dysautonomia, familia	NM_003640.5:c.3332delC, NM_003640.5:c.2741C>T, NM_003640.5:c.2328delT, NM_003640.5:c.2204+6T>C, NM_003640.5:c.2087G>C, NM_003640.5:c.2087G>A, NM_003640.5:c.1460+2T>C
IL11RA	Crigler-Najjar Syndrom	e NM_001142784.3:c3327A>G
IL2RG	Severe Combined Immunodeficiency, X-L	NM_000206.3:c.854G>A, NM_000206.3:c.664C>T, NM_000206.3:c.454+1G>A, NM_000206.3:c.452T>C, NM_000206.3:c.355A>T, NM_000206.3:c.343T>C, NM_000206.3:c.341G>A, NM_000206.3:c.186T>A
IVD	Isovaleric acidemia	NM_002225.5:c.149G-X, NM_002225.5:c.1257-C, NM_002225.5:c.148C>T, NM_002225.5:c.149G-A, NM_002225.5:c.149G-A, NM_002225.5:c.381-49G-X, NM_002225.5:c.31381-41384-4616G-X, NM_002225.5:c.1174C>T, NM_002225.5:c.1177deIT, NM_002225.5:c.1183C>T, NM_002225.5:c.1193A>G
LAMA2	LAMA2-related Muscu Dystrophy	NM_000426.4::2045_2046fel.46G, NM_000426.4::2750-165-C, NM_000426.4::2323-2A>T, NM_000426.4::2451-2A-5G, NM_000426.4::2750-165-C, NM_000426.4::2901C-A, NM_000426.4::2962C>T, NM_000426.4::32512eleG, NM_000426.4::2372C>A, NM_000426.4::32512eleG, NM_000426.4::2372C>A, NM_000426.4::32620_3642delCCAAGG6CATTGTTTTTCAACAT, NM_000426.4::3629delT, NM_000426.4::50506>T, NM_000426.4::2527C>T, NM_000426.4::4505C>T, NM_000426.4::50506>T, NM_000426.4::2527C>T, NM_000426.4::608delA, NM_000426.4::6037delT, NM_000426.4::6334A>T, NM_000426.4::52727ST, NM_000426.4::608delA, NM_000426.4::6555C>T, NM_000426.4::6334A>T, NM_000426.4::727278delCT, NM_000426.4::7534delC, NM_000426.4::732C>T, NM_000426.4::7272728delCT, NM_000426.4::7534delC, NM_000426.4::732C>T, NM_000426.4::7810C>T, NM_000426.4::738delA, NM_000426.4::6864C>G, NM_000426.4::7810C>T, NM_000426.4::2573delCT, NM_000426.4::2533C>T, NM_000426.4::6868d
LAMA3	Epidermolysis bullosa, junctional, Herlitz type related)	NM_198129.4:c.5160delG, NM_198129.4:c.6009delG, NM_198129.4:c.6808C>T, NM_198129.4:c.6943A>T, NM_198129.4:c.7489C>T, NM_198129.4:c.8177+2T>G, NM_198129.4:c.8962C>T,



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
LAMB3	Epidermolysis bullosa, junctional, Herlitz type related)	
LAMC2	Epidermolysis bullosa, junctional, Herlitz type related)	
LIFR	Stuve-Wiedemann syndrome/Schwartz-Ja 2 syndrome	NM_001127671.2:c.2503G>T, NM_001127671.2:c.2013dupT, NM_001127671.2:c.1789C>T, NM_001127671.2:c.1018_1022deIAATTG, NM_001127671.2:c.653dupT, NM_001127671.2:c.171_174deITAAC
LOXHD	L Deafness, autosomal ro 77	ecessive NM_001384474.1:c.4714C5T, NM_001384474.1:c.4524_4525de1AG, NM_001384474.1:c.452665A, NM_001384474.1:c.452665A, NM_001384474.1:c.3874C5T, NM_001384474.1:c.2008C5T, NM_001384474.1:c.512-1G>A, NM_001384474.1:c.457_461dupCGCCA, NM_001384474.1:c.27>A
LRPPRC	Leigh Syndrome, Frenc Canadian Type	h- NM_133259.4:c.3830_3837delGTGGTGCA, NM_133259.4:c.1061C>T
MAN2B	1 Alpha-Mannosidosis	NM_000528.4:c.2686_2687delCTinsG, NM_000528.4:c.2436+2T>C, NM_000528.4:c.2426T>C, NM_000528.4:c.24016>T, NM_000528.4:c.23986>A, NM_000528.4:c.2368C>T, NM_000528.4:c.218C>T, NM_000528.4:c.2119C>T, NM_000528.4:c.2013delT, NM_000528.4:c.1929G>A, NM_000528.4:c.1915C>T, NM_000528.4:c.1830+1G>C, NM_000528.4:c.21780C>T, NM_000528.4:c.1259G>T, NM_000528.4:c.1067C>G, NM_000528.4:c.384G>A, NM_000528.4:c.215A>T, NM_000528.4:c.1A>G
MAT1A	Hypermethioninemia	NM_000429.3:c.1070C>T, NM_000429.3:c.1043_1044deITG, NM_000429.3:c.1006G>A, NM_000429.3:c.966T>G, NM_000429.3:c.914T>C, NM_000429.3:c.827_828insG, NM_000429.3:c.791G>A, NM_000429.3:c.790C>T, NM_000429.3:c.595C>T, NM_000429.3:c.538_539insTG
MCCC1	3-Methylcrotonyl-CoA carboxylase 1 deficiend	CY NM_020166.5:c.2079delA, NM_020166.5:c.1942G>A, NM_020166.5:c.1930G>T, NM_020166.5:c.1905delA, NM_020166.5:c.1526delG, NM_020166.5:c.130T-G, NM_020166.5:c.1310T>C, NM_020166.5:c.1572delG, NM_020166.5:c.15740elG, SC, NM_020166.5:c.1074delG, SC, NM_020166.5:c.1074delG, SC, NM_020166.5:c.1074delG, SC, NM_020166.5:c.343C+T, NM_020166.5:c.558delA, NM_020166.5:c.558delA, NM_020166.5:c.343C+T, NM_020166.5:c.343C+T, NM_020166.5:c.340C+T
MCCC2	3-Methylcrotonyl-CoA carboxylase 2 deficienc	NM_022132.5:c.296G>C, NM_022132.5:c.380C>G, NM_022132.5:c.464G>A, NM_022132.5:c.499T>C, NM_022132.5:c.515_516InsT, NM_022132.5:c.639dEG, NM_022132.5:c.729_730InsC, NM_022132.5:c.383G>T, NM_022132.5:c.929C>G, NM_022132.5:c.94C>T, NM_022132.5:c.1056>A, NM_022132.5:c.1056>T, NM_022132.5:c.1072+1G>A, NM_022132.5:c.1309A>G, NM_022132.5:c.1367C>T, NM_022132.5:c.1576_1577insT, NM_022132.5:c.1580G>A
MCOLN	1 Mucolipidosis IV	NM_020533.3:c.304C>T, NM_020533.3:c.964C>T, NM_020533.3:c.1084G>T, NM_020533.3:c.1207C>T
MECP2	RETT Syndrome	NM_001110792.2:c.1318G>A, NM_001110792.2:c.1084_1086delAGC, NM_001110792.2:c.1001<>T, NM_00110792.2:c.1000C>T, NM_001110792.2:c.952C>T, NM_001110792.2:c.946C>T, NM_001110792.2:c.7896 <t, nm_001110792.2:c.742delg,="" nm_001110792.2:c.796c="">T, NM_001110792.2:c.789delC, NM_001110792.2:c.766C>T, NM_001110792.2:c.741G>A, NM_001110792.2:c.739C>G, NM_001110792.2:c.710C>T, NM_001110792.2:c.647C>G, NM_001110792.2:c.538C>T, NM_001110792.2:c.251dupC</t,>
MEFV	Familial Mediterranear	NM_000243.3:c.2282G>A, NM_000243.3:c.2230G>T, NM_000243.3:c.2177T>C, NM_000243.3:c.2084A>G, NM_000243.3:c.2082G>A, NM_000243.3:c.2080A>G, NM_000243.3:c.2076_2078deIAAT, NM_000243.3:c.208C>C, NM_000243.3:c.2040G>A, NM_000243.3:c.1757G> NM_000243.3:c.2080A>G, NM_000243.3:c.2040G>A, NM_000243.3:c.1958G>A, NM_000243.3:c.1772T>C, NM_000243.3:c.2040G>C, NM_000243.3:c.1240G>A, NM_000243.3:c.1958G>A, NM_000243.3:c.1016C>T, NM_000243.3:c.8437C6, NM_000243.3:c.123G>A, NM_000243.3:c.1141C>T, NM_000243.3:c.1016C>T, NM_000243.3:c.8437C5, NM_000243.3:c.688G>A, NM_000243.3:c.656dupG, NM_000243.3:c.501G>C, NM_000243.3:c.443A>T, NM_000243.3:c.163dupA
MFSD8	Ceroid Lipofuscinosis, I 7	Neuronal, NM_001371596.2:c.1525_1526delCT, NM_001371596.2:c.1286G>A, NM_001371596.2:c.1235C>T, NM_001371596.2:c.1090delA, NM_001371596.2:c.929CA>G, NM_001371596.2:c.929G>A, NM_001371596.2:c.894T>G, NM_001371596.2:c.881C>A, NM_001371596.2:c.362A>G
MKKS	Bardet-Biedl Syndrome	26 NM_170784.3:c.1436C>G, NM_170784.3:c.1225_1226delGG, NM_170784.3:c.830T>C, NM_170784.3:c.724G>T, NM_170784.3:c.353delG, NM_170784.3:c.250C>T
MKS1	Bardet-Biedl syndrome 13/Joubert syndrome syndrome 1	28/Meckel
MLC1	Megalencephalic leukoencephalopathy subcortical cysts	MM_015166.4:c.839C-T, NM_015166.4:c.424-2A>C, NM_015166.4:c.423C-A, NM_015166.4:c.422A>G, NM_015166.4:c.278C>T, NM_015166.4:c.274C>T, NM_015166.4:c.206C>T, NM_015166.4:c.135dupC, NM_015166.4:c.33dupC
MLYCD	Malonyl-CoA decarbox deficiency	ylase NM_012213.3:c.560C>G, NM_012213.3:c.679_680insTGAAGC, NM_012213.3:c.755delT



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME		VAR NAME
· · · · · · · · · · · · · · · · · · ·			
MMAA	Methylmalonic Aciduri Related	NM_172250.3:c.451de NM_172250.3:c.811G>	.T, NM_172250.3:c.387C>A, NM_172250.3:c.440G>A, NM_172250.3:c.447_448insG, IC, NM_172250.3:c.503delC, NM_172250.3:c.586C>T, NM_172250.3:c.620A>G, -T, NM_172250.3:c.1032delT
MMAB	Methylmalonic Aciduri Related	IVIIVIAB- NM_052845.4:c.557G>	rT, NM_052845.4:c.577G>A, NM_052845.4:c.569G>A, NM_052845.4:c.568C>T, A, NM_052845.4:c.556C>T, NM_052845.4:c.548A>T, NM_052845.4:c.220G>T, G>T, NM_052845.4:c.197-1G>A
MMACHC	Cobalamin C disease	NM_015506.3:c.382_3 NM_015506.3:c.440G> NM_015506.3:c.608G>	17JinsA, NM_015506.3:: 331C-7i, NM_015506.3:: 347T-C, 184delTAC, NM_015506.3:: 388T-C, NM_015506.3:: 389A-G, NM_015506.3:: 394C-T, C, NM_015506.3:: 481C-T, NM_015506.3:: 482G-A, NM_015506.3:: 634_545delTG, -A, NM_015506.3:: 609G-A, NM_015506.3:: 615C-A, NM_015506.3:: 615C-G, 117insG, NM_015506.3:: 616C-T, NM_015506.3:: 655_658delAGA, -T
MMADHC	Homocystinuria, cblD t variant 1/Methylmalor aciduria and homocyst cblD type/Methylmalo aciduria, cblD type, var	Uria, C	μpT, NM_015702.3:c.776T>C, NM_015702.3:c.748C>T, NM_015702.3:c.746A>G, G, NM_015702.3:c.545C>A, NM_015702.3:c.478+1G>T, NM_015702.3:c.419dupA, deICTCTTTAG
MMUT	Methylmalonic acidem	NM_000255.4:c.1867G NM_000255.4:c.1420C NM_000255.4:c.181T NM_000255.4:c.671_6 NM_000255.4:c.6767G	>T, NM_000255.4:c.2080C>T, NM_000255.4:c.1924G>C, NM_000255.4:c.1871A>G, >>A, NM_000255.4:c.1741C>T, NM_000255.4:c.1658detT, NM_000255.4:c.1445:24>G, >T, NM_000255.4:c.1399C>T, NM_000255.4:c.1280G>A, NM_000255.4:c.1207C>T, >A, NM_000255.4:c.130G>A, NM_000255.4:c.9147>C, NM_000255.4:c.682C>T, 798dupAnTTATC1, NM_000255.4:c.653A2T, NM_000255.4:c.6343C>A, >A, NM_000255.4:c.572C>A, NM_000255.4:c.313T>C, NM_000255.4:c.280G>A, >A, NM_000255.4:c.91C>T
MOCS1	Molybdenum cofactor A		127C>T, NM_001358530.2:c.956G>A, NM_001358530.2:c.397_406delCCGGACGTGG, 8G>A, NM_001358530.2:c.217C>T
MPI	Congenital disorder of glycosylation, type Ib	NM_002435.3:c.982C>	-T, NM_002435.3:c.413T>C, NM_002435.3:c.656G>A, NM_002435.3:c.884G>A, T, NM_002435.3:c.1016_1019deIACCC
MPV17	Mitochondrial DNA de syndrome	ECION NM_002437.5:c.263_2 NM_002437.5:c.70G>T	
MTHFR	Homocystinuria due to deficiency	NM_005957.5:c.968T>	lelC, NM_005957.5:c.1743G>A, NM_005957.5:c.1129C>T, NM_005957.5:c.971A>G, C, NM_005957.5:c.547C>T, NM_005957.5:c.439C>T, NM_005957.5:c.3G>A
MTM1	Myotubular Myopathy	K-LINKEO NM_000252.3:c.670C> NM_000252.3:c.963de	I, NM_000252.3::c.420C-G, NM_000252.3::c.461T-G, NM_000252.3::c.594_598delCCCTG, T, NM_000252.3::c.721C>T, NM_000252.3::C.780T>A, NM_000252.3::c.962_963insA, IA, NM_000252.3::c.1261-10A>G, NM_000252.3::c.1304_1305insTCCTA, 1357delCC, NM_000252.3::c.1415_1416delGT
MTTP	Abetalipoproteinemia		13_704delAC, NM_001386140.1:c.1619G>A, NM_001386140.1:c.1769G>T, 67+1G>A, NM_001386140.1:c.2030delC, NM_001386140.1:c.2593G>T
MYO15A	Deafness, autosomal ro	ESSIVE 3 NM_016239.4:c.33850 NM_016239.4:c.4750 NM_016239.4:c.60034 NM_016239.4:c.6863 NM_016239.4:c.8429	T, NM_016239.4:c.754, 755insA, NM_016239.4:c.3313G>T, NM_016239.4:c.334delG, >T, NM_016239.4:c.3693-2A>G, NM_016239.4:c.3756+16>T, NM_016239.4:c.3351G>A, 4751insTC, NM_016239.4:c.5326C>T, NM_016239.4:c.5426Z>T, lelG, NM_016239.4:c.6046+2T>G, NM_016239.4:c.6514C>T, NM_016239.4:c.6743C>T, 6873delCGGACTGGAG, NM_016239.4:c.8146C>T, NM_016239.4:c.8410A>T, 8447delGCGGGCAGCTGCGGGTCCT, NM_016239.4:c.8548C>T, 9959delCTGA, NM_016239.4:c.10573delA
ΜΥΟ7Α	Usher syndrome, type	 NM_000260.4::634C NM_000260.4::1184G NM_000260.4::1184G NM_000260.4::1384T NM_000260.4::3134T NM_000260.4::3595 NM_000260.4::3597 NM_000260.4::5507T NM_000260.4::5507T 	NM_000260.4::133-2A-G, NM_000260.4::C448C>T, NM_000260.4::449C>T, T, NM_000260.4::635G>A, NM_000260.4::C40G>A, NM_000260.4::731G>C, S-A, NM_000260.4::1344-1G>A, NM_000260.4::1797G>A, NM_000260.4::1884C>A, S-T, NM_000260.4::2023C>T, NM_000260.4::2476G>A, NM_000260.4::2617C>T, S-C, NM_000260.4::2023C>T, NM_000260.4::2376G>A, NM_000260.4::2617C>T, S-C, NM_000260.4::2319G>A, NM_000260.4::3524G>A, 3396iin3T, NM_000260.4::3719G>A, NM_000260.4::53624GA, S-A, NM_000260.4::26162A, NM_000260.4::5227C>T, NM_000260.4::5392C>T, SG, NM_000260.4::2516G>A, NM_000260.4::5824G>T, S887delTTCT, NM_000260.4::597C-G, NM_000260.4::6024delG
NAGS	N-acetylglutamate Syn Deficiency	NM_153006.3:c.12996	A>T, NM_153006.3:c.971G>A, NM_153006.3:c.1025delG, NM_153006.3:c.1289T>C, >C, NM_153006.3:c.1306_1307insT
NDRG1	Charcot-Marie-Tooth D type 4D	NM_006096.4:c18-2_	-
NEB	Nemaline myopathy 2, autosomal recessive	16>Ā, NM_001164507 NM_001164507.2:c.23 NM_001164507.2:c.21 NM_001164507.2:c.21 NM_001164507.2:c.61	404+1_25404+2insATGGA, NM_001164507.2:c.25174G-T, NM_001164507.2:c.24874- 2:c:24687_24688delGA, NM_001164507.2:c.24655_24666delTT, 989C-T, NM_001164507.2:c.23421_23422delAG, NM_001164507.2:c.21945+1G>A, 076C-T, NM_001164507.2:c.19285_19286delGCinsAA, 203_12204delTG, NM_001164507.2:c.58031_8041delAAATAAACGAG, 05dupT, NM_001164507.2:c.55676-A, NM_001164507.2:c.3191A>G, 73G>T, NM_001164507.2:c.843T>G



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME		VAR NAME
NPC1	Niemann-Pick disease,	type C1	NM_000271.5:c.3662delT, NM_000271.5:c.3611_3614delTTAC, NM_000271.5:c.3467A>G,
		())) ()	NM_000271.5:c.3425T>C, NM_000271.5:c.3182T>C, NM_000271.5:c.3175 <t, nm_000271.5:c.3107c="">T, NM_000271.5:c.3104C>T, NM_000271.5:c.2974G>T, NM_000271.5:c.2974G>T, NM_000271.5:c.2974G>T, NM_000271.5:c.2932C>T, NM_000271.5:c.2933G>A, NM_000271.5:c.2934G>A, NM_000271.5:c.2932C>T, NM_000271.5:c.2933G>A, NM_000271.5:c.2932C>T, NM_000271.5:c.2948G>A, NM_000271.5:c.2932C>T, NM_000271.5:c.2932C>T, NM_000271.5:c.2932C>T, NM_000271.5:c.2946G>A, NM_000271.5:c.2932C>T, NM_000271.5:c.2972C>T, NM_000271.5:c.2972C>T,</t,>
NPC2	Niemann-pick disease,	type C2	NM_006432.5:c.441+1G>A, NM_006432.5:c.436C>T, NM_006432.5:c.358C>T, NM_006432.5:c.352G>T, NM_006432.5:c.295T>C, NM_006432.5:c.190+5G>A, NM_006432.5:c.115G>A, NM_006432.5:c.58G>T, NM_006432.5:c.27delG
NPHP1	Juvenile Nephronopht	hisis	NM_001128178.3:c.1716+1G>T, NM_001128178.3:c.1016dupC, NM_001128178.3:c.771+58C>T, NM_001128178.3:c.555dupA, NM_001128178.3:c.455C>G, NM_001128178.3:c.80T>A, NM_001128178.3:c.1deIA
NPHS1	Nephrotic syndrome, t	ype 1	NM_004646.4:c.3478C>T, NM_004646.4:c.3325C>T, NM_004646.4:c.3109+1G>A, NM_004646.4:c.2928G>T, NM_004646.4:c.2746G>T, NM_004646.4:c.2491C>T, NM_004646.4:c.2464G>A, NM_004646.4:c.2456A>T, NM_004646.4:c.2175G>A, NM_004646.4:c.1481del(C, N04646.4:c.307_1308dupAC, NM_004646.4:c.1212_AUM_004646.4:c.59-5C>G
NR0B1	Congenital Adrenal Hy X-linked	poplasia,	NM_000475.5:c.1319A>T, NM_000475.5:c.1316T>G, NM_000475.5:c.1107G>A, NM_000475.5:c.890T>C, NM_000475.5:c.873G>C, NM_000475.5:c.847C>T, NM_000475.5:c.813C>G, NM_000475.5:c.800G>C, NM_000475.5:c.788T>A, NM_000475.5:c.704G>A, NM_000475.5:c.591C>A, NM_000475.5:c.313G>A, NM_000475.5:c.388_389deITA, NM_000475.5:c.315G>C, NM_000475.5:c.273C>A
NR2E3	Enhanced S-cone synd	rome	NM_014249.4:c.119-2A>C, NM_014249.4:c.226C>T, NM_014249.4:c.227G>A, NM_014249.4:c.297_298delGT, NM_014249.4:c.361G>A, NM_014249.4:c.932G>A, NM_014249.4:c.1034_1038delTGCAG
NTRK1	Insensitivity to pain, co with anhidrosis	ongenital,	NM_002529.4:c.1076A>G, NM_002529.4:c.1474G>A, NM_002529.4:c.1726deT, NM_002529.4:c.1726d>C, NM_002529.4:c.1759A>G, NM_002529.4:c.1870C>T, NM_002529.4:c.1926_1927insT, NM_002529.4:c.1960C>T, NM_002529.4:c.2084C>T, NM_002529.4:c.2339G>C
OAT	Ornithine Aminotransf Deficiency	erase	NM_000274.4:c.1276C>T, NM_000274.4:c.1250C>T, NM_000274.4:c.1205T>C, NM_000274.4:c.294G>A, NM_000274.4:c.954C>T, NM_000274.4:c.952G>A, NM_000274.4:c.912A>C, NM_000274.4:c.924G>A, NM_000274.4:c.924G>A, NM_000274.4:c.924G>A, NM_000274.4:c.924G>A, NM_000274.4:c.924G>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.995C>A, NM_000274.4:c.927A>A, NM_00027A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_000274.4:c.927A>A, NM_00027A, NM_00027
OCRL	Lowe syndrome, X-Link	ked	NM_000276.4:c.903_904deIAG, NM_000276.4:c.1499G>A, NM_000276.4:c.2299C>T, NM_000276.4:c.2402_2403insA, NM_000276.4:c.2530C>T, NM_000276.4:c.2534deIA
отс	Ornithine transcarbam deficiency	iylase	NM_000531.6:c.776>A, NM_000531.6:c.118C>T, NM_000531.6:c.119G>A, NM_000531.6:c.1347>C NM_000531.6:c.2480>T, NM_000531.6:c.238A>G, NM_000531.6:c.2457>G, NM_000531.6:c.259G>A, NM_000531.6:c.275G>A, NM_000531.6:c.327C, NM_000531.6:c.421C>T, NM_000531.6:c.4606>T, NM_000531.6:c.563G>T, NM_000531.6:c.589G>T, NM_000531.6:c.6177>G, NM_000531.6:c.646C>G, NM_000531.6:c.674C>T, NM_000531.6:c.717+27>C, NM_000531.6:c.829C>T
РАН	Phenylalanine hydroxy deficiency (including phenylketonuria)	lase	NM_000277.3:c.1315+1G>A, NM_000277.3:c.1243G>A, NM_000277.3:c.1241A>G, NM_000277.3:c.1238G>C, NM_000277.3:c.1232G>T, NM_000277.3:c.1238G>C, NM_000277.3:c.1238G>C, NM_000277.3:c.1238G>C, NM_000277.3:c.1396>T, NM_000277.3:c.3956>T, NM_000277.3:c.326>T, NM_000277.3:c.336>T, NM_000277.3:c.336>T, NM_000277.3:c.3956>T, NM_000277.3:c.326>T, NM_000277.3:c.336>T, NM_000277.3:c.336>T, NM_000277.3:c.326>T, NM_000277.3:c.736>T, NM_000277.3:c.737>T, NM_00277.3:c.737>T, NM_000277.3:c.737>T, NM_00277.3:c.737>T, NM
PANK2	Pantothenate Kinase-A Neurodegeneration	ssociated	NM_001386393.1:c.460C>T, NM_001386393.1:c.491_492delCT, NM_001386393.1:c.881A>T, NM_001386393.1:c.1231G>A, NM_001386393.1:c.1253C>T
РС	Pyruvate Carboxylase I	Deficiency	NM_001040716.2:c.1748G>T, NM_001040716.2:c.496G>A, NM_001040716.2:c.434T>C
PCCA	Propionic acidemia		NM_000282.4:c.229C>T, NM_000282.4:c.259_260insT, NM_000282.4:c.412G>A, NM_000282.4:c.600+1G>A, NM_000282.4:c.620+1G>A, NM_000282.4:c.124, 1225delT, NM_000282.4:c.1284+1G>A, NM_000282.4:c.1224_1225delTT, NM_000282.4:c.1284+1G>A, NM_000282.4:c.1594_1597delTTGT, NM_000282.4:c.1891G>C, NM_000282.4:c.1899+1_1899+14delGTAA



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
I		
РССВ	Propionicacidemia	NM_000532.5:c.331C>T, NM_000532.5:c.337C>T, NM_000532.5:c.502G>A, NM_000532.5:c.562G>A, NM_000532.5:c.683C>T, NM_000532.5:c.737G>T, NM_000532.5:c.5984_9851in5T, NM_000532.5:c.1059_1170in5T, NM_000532.5:c.1281_2314e166GCATCATCCG6Cin5TAGAGCACAGGA, NM_000532.5:c.1219_1224delGGCATCinsAA, NM_000532.5:c.1223_1226delTCAT, NM_000532.5:c.1228C>T, NM_000532.5:c.1229_1230insT, NM_000532.5:c.1283C>T, NM_000532.5:c.1304A>G, NM_000532.5:c.1209_1230insT, NM_000532.5:c.1534C>T, NM_000532.5:c.1307_1538insCCC, NM_000532.5:c.1606A>G
PCDH15	Usher syndrome, type	1F NM_033056.4:c.5724_57550delACGCACAAATGTTTCAGAACTTCAAACTAGTA, NM_033056.4::c.5659A>T, NM_033056.4:c.5424_57550delACGCACAAATGTTTCAGAACTTCAAACTAGTA, NM_033056.4::c.48654delA, NM_033056.4::c.4584_4551dupATCT, NM_001384140.1::c.3782-A>G, NM_001384140.1::c.2645_2646delAT, NM_001384140.1::c.19840erT, NM_001384140.1::c.1737C>G, NM_001384140.1::c.1883T>A, NM_001384140.1::c.1088derT, NM_001384140.1::c.1021C>T, NM_001384140.1::c.1006C>T, NM_001384140.1::c.7565>A, NM_001384140.1::c.400C>T, NM_001384140.1::c.400C>G, NM_001384140.1::c.7C>T
PDHA1	Pyruvate Dehydrogena Deficiency, X-Linked	
PEX1	Peroxisome biogenesis 1A (Zellweger)	disorder NM_000466.3:c.3505_3517delCAGTIGTITTCAC, NM_000466.3:c.2916delA, NM_000466.3:c.2528G>A, NM_000466.3:c.2097dupT, NM_000466.3:c.1991T>C, NM_000466.3:c.1952_1960dupCAGTGTGGA, NM_000466.3:c.1842delA, NM_000466.3:c.1239+1G>T, NM_000466.3:c.877C>T
PEX12	Peroxisome Biogenesis 3A (Zellweger)	
PEX2	Peroxisome biogenesis 5A (Zellweger)	
PEX7	Rhizomelic chondrody punctata type 1	NM_000288.4:c.903+1G>C
PKHD1	Polycystic kidney disea autosomal recessive	Se, NM_138694.4:c.12027C-G, NM_138694.4:c.1161T-C, NM_138694.4:c.1353_1372delCTTCCCTGGA, NM_138694.4:c.10515C-A, NM_138694.4:c.10452dupT, NM_138694.4:c.10515C-A, NM_138694.4:c.10452dupT, NM_138694.4:c.10515C-A, NM_138694.4:c.10452dupT, NM_138694.4:c.10515C-A, NM_138694.4:c.10452dupT, NM_138694.4:c.9866C-T, NM_138694.4:c.9007-C, NM_194.5007-C, NM_19
PLA2G6	Infantile neuroaxonal o 1	NM_003560.4:c.2370T>G, NM_003560.4:c.2239C>T, NM_003560.4:c.1903C>T, NM_003560.4:c.1894C>T, NM_003560.4:c.1894C>T, NM_003560.4:c.1894C>T, NM_003560.4:c.1903C>T, NM_003560.4:c.238G>A, NM_003560.4:c.19C>T
PMM2	Congenital disorder of glycosylation type la	NM_000303.3:c.26G>A, NM_000303.3:c.53C>G, NM_000303.3:c.95_96delTAinsGC, NM_000303.3:c.95T>G, NM_000303.3:c.97C>T, NM_000303.3:c.190C>T, NM_000303.3:c.127G<-, NM_000303.3:c.131T>C, NM_000303.3:c.190delT, NM_000303.3:c.193C>T, NM_000303.3:c.255+2T>C, NM_000303.3:c.256-15>C, NM_000303.3:c.357C>A, NM_000303.3:c.356C>A, NM_000303.3:c.255+2T>C, NM_000303.3:c.395T>C, NM_000303.3:c.357C>A, NM_000303.3:c.356C>A, NM_000303.3:c.435C>A, NM_000303.3:c.395T>C, NM_000303.3:c.455A, NM_000303.3:c.426C>A, NM_000303.3:c.427C>C, NM_000303.3:c.470>C, NM_000303.3:c.470>C, NM_000303.3:c.553A>G, NM_000303.3:c.426C>A, NM_000303.3:c.626C>C, NM_000303.3:c.474>T, NM_000303.3:c.552C>A, NM_000303.3:c.426C>A, NM_000303.3:c.472C>C, NM_000303.3:c.647A>T, NM_000303.3:c.552C>A, NM_000303.3:c.70C>C, NM_00303.3:c.647A>T, NM_000303.3:c.552C>A, NM_000303.3:c.70C>C, NM_00303.3:c.647A>T, NM_000303.3:c.752C>A, MM_000303.3:c.70C>C, NM_00303.3:c.647A>T, NM_000303.3:c.752C>A, MM_000303.3:c.70C>C, NM_00303.3:c.647A>T, NM_000303.3:c.70C>G, NM_000303.3:c.70C>T
PNPO	Pyridoxal 5'-phosphate dependent epilepsy	NM_018129.4:c.674G>A, NM_018129.4:c.685C>T
POLG	POLG-Related Disorder	S NM_002693.3:c.3644-1G>A, NM_002693.3:c.3630dupC, NM_002693.3:c.3286C>T, NM_002693.3:c.3218C>T, NM_002693.3:c.31516>C, NM_002693.3:c.22794C>T, NM_002693.3:c.2567C>T, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.257C, NM_002693.3:c.157C, NM_002693.3:c.752C,
POMGNT1	Muscle-Eye-Brain Dise POMGNT1-Related	DSCP, NM_017739.4:c.1864delC, NM_017739.4:c.1814G>C, NM_017739.4:c.1666G>A, NM_017739.4:c.1545delC, NM_017739.4:c.1539+1G>A, NM_017739.4:c.1666G>A, NM_017739.4:c.1466G>A, NM_017739.4:c.1466G>A, NM_017739.4:c.01766G>A, NM_017739.4:c.017676G>A, NM_017739.4:c.017676G>A, NM_017739.4:c.017739.4:c
PPT1	Ceroid Lipofuscinosis, 1	NM_000310.4:c.4240dupA, NM_000310.4:c.627+1G>T, NM_000310.4:c.541G>T, NM_000310.4:c.451C>T, NM_000310.4:c.223A>C, NM_000310.4:c.29T>A



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME		VAR NAME
i			
PROP1	Combined Pituitary Ho Deficiency 2	rmone	NM_006261.5:c.469dupT, NM_006261.5:c.373C-T, NM_006261.5:c.358C-T, NM_006261.5:c.349T-A, NM_006261.5:c.310delC, NM_006261.5:c.301_302delAG, NM_006261.5:c.295C-T, NM_006261.5:c.257C-T, NM_006261.5:c.257C-T, NM_006261.5:c.257C-T, NM_006261.5:c.157delA, NM_006261.5:c.217C-T, NM_006261.5:c.218G-X, NM_006261.5:c.275T, NM_006261.5:c.157delA, NM_006261.5:c.217C-T, NM_006261.5:c.31263A, NM_006261.5:c.257C, NM_006261.5:c.34delG, NM_006261.5:c.217C-T, NM_006261.5:c.343-11C>G
PRPS1	Arts syndrome, X-Linke	ed	NM_002764.4:c.193G>A, NM_002764.4:c.344T>C, NM_002764.4:c.398A>C, NM_002764.4:c.455T>C, NM_002764.4:c.869T>C, NM_002764.4:c.916G>A
PSAP	Metachromatic Leukoc PSAP-Related	lystrophy,	NM_002778.4:c.1288C>T, NM_002778.4:c.1046T>C, NM_002778.4:c.643A>C, NM_002778.4:c.607C>T, NM_002778.4:c.1A>T
PYGM	McArdle disease		NM_005609.4:c.239217-c, NM_005609.4:c.2262delA, NM_005609.4:c.2128_2130delTTC, NM_005609.4:c.2009-CT, NM_005609.4:c.1963G>A, NM_005609.4:c.1827G>A, NM_005609.4:c.17864-1G>A, NM_005609.4:c.1726C-T, NM_005609.4:c.19217-G, NM_005609.4:c.1628A>C, NM_005609.4:c.16216>T, NM_005609.4:c.1466C>G, NM_005609.4:c.1094C>T, NM_005609.4:c.1613C>A, NM_005609.4:c.25104upT, NM_005609.4:c.481C>T, NM_005609.4:c.393delG, NM_005609.4:c.280C>T, NM_005609.4:c.255C>A, NM_005609.4:c.148C>T, NM_005609.4:c.13_14delCT, NM_005609.4:c.1A>G
RAB23	Carpenter Syndrome		NM_016277.5:c.434T>A, NM_016277.5:c.407dupC
RAG1	Omenn syndrome / T- combined immunodefi		NM_000448.3:c.256_257deIAA_NM_000448.3:c.940C-T_NM_000448.3:c.9836-A_NM_000448.3:c.1681C-T, NM_000448.3:c.1682G-A, NM_000448.3:c.2164G-A, NM_000448.3:c.2326G-T, NM_000448.3:c.2326C-T, NM_000448.3:c.2333G-A, NM_000448.3:c.2814T-6, NM_000448.3:c.2923C-T, NM_000448.3:c.3016A-6
RAG2	Omenn syndrome / T- combined immunodefi		NM_000536.4:c.1504A>G, NM_000536.4:c.1352G>C, NM_000536.4:c.686G>A, NM_000536.4:c.685C>T, NM_000536.4:c.601C>T, NM_000536.4:c.283G>A, NM_000536.4:c.230C>A, NM_000536.4:c.115A>G
RAPSN	Myasthenic syndrome, congenital, 11, associa acetylcholine receptor	ted with	NM_005055.5:c.848T>C, NM_005055.5:c.807C>A, NM_005055.5:c.603C>A, NM_005055.5:c.566C>T, NM_005055.5:c.490C>T, NM_005055.5:c.484G>A, NM_005055.5:c.416T>C, NM_005055.5:c.264C>A
RDH12	Leber congenital amau	rosis 13	NM_152443.3:c.146C-T, NM_152443.3:c.152T-A, NM_152443.3:c.164C-T, NM_152443.3:c.184C-T, NM_152443.3:c.209_210insC, NM_152443.3:c.295C-A, NM_152443.3:c.377C-T, NM_152443.3:c.379G-T, NM_152443.3:c.448+1_448+4delGTAA, NM_152443.3:c.451C-A, NM_152443.3:c.451C-G, NM_152443.3:c.464C-T, NM_152443.3:c.523T-C, NM_152443.3:c.565C-T, NM_152443.3:c.677A>G, NM_152443.3:c.805_809delGCCCT
RLBP1	Bothnia retinal dystrophy/Fundus albipunctatus/Retinitis albescens	punctata	NM_000326.5:c.875C>T, NM_000326.5:c.700C>T, NM_000326.5:c.452G>A, NM_000326.5:c.333T>G
RPE65	Leber congenital amau	rosis 2	NM_000329.3:c.1543C-T, NM_000329.3:c.1355T>G, NM_000329.3:c.1301C>T, NM_000329.3:c.1292A>G, NM_000329.3:c.1102T>C, NM_000329.3:c.1087C>A, NM_000329.3:c.1022T>C, NM_000329.3:c.97A>T, NM_000329.3:c.881A>C, NM_000329.3:c.514_515delGT, NM_000329.3:c.394G>A, NM_000329.3:c.272G>A, NM_000329.3:c.271C>T
RPGRIP1L	Ciliopathies, RPGRIP1L	-Related	NM_015272.5:c.3706C>T, NM_015272.5:c.3634_3637delGAAA, NM_015272.5:c.3548C>G, NM_015272.5:c.2794_2795deITT, NM_015272.5:c.2614C>T, NM_015272.5:c.2413C>T, NM_015272.5:c.2050C>T, NM_015272.5:c.2030C>T, NM_015272.5:c.1975>C, NM_015272.5:c.1843A>C, NM_015272.5:c.1326_1329delAAA, NM_015272.5:c.393dupA, NM_015272.5:c.1776>A, NM_015272.5:c.776+16>A, NM_015272.5:c.757C>T, NM_015272.5:c.697A>T, NM_015272.5:c.394A>T
SACS	Autosomal Recessive S Ataxia of Charlevoix-Sa		NM_014363.6:c.13237C>T, NM_014363.6:c.12160C>T, NM_014363.6:c.11624G>A, NM_014363.6:c.10954C>A, NM_014363.6:c.10907G>A, NM_014363.6:c.8844detT, NM_014363.6:c.8107C>T, NM_014363.6:c.7504C>T, NM_014363.6:c.7501C>A, NM_014363.6:c.65631>A, NM_014363.6:c.555C>T, NM_014363.6:c.5618_5619delAT, NM_014363.6:c.4933C>T, NM_014363.6:c.3198T>A, NM_014363.6:c.394A>T, NM_014363.6:c.517C>T
SBDS	Shwachman-Diamond	syndrome	NM_016038.4:c.652C>T, NM_016038.4:c.505C>T, NM_016038.4:c.377G>C, NM_016038.4:c.258+2T>C, NM_016038.4:c.183_184deITAinsCT, NM_016038.4:c.184A>T, NM_016038.4:c.127G>T, NM_016038.4:c.120deIG
SERPINA1	Alpha-1-antitrypsin de	ficiency	NM_000295.5:c.1177C-T, NM_000295.5:c.1093G>A, NM_000295.5:c.848A>T, NM_000295.5:c.839A>T, NM_000295.5:c.739C-T, NM_000295.5:c.514G>T, NM_000295.5:c.514G>A, NM_000295.5:c.415G>A, NM_000295.5:c.347T>A, NM_000295.5:c.272G>A, NM_000295.5:c.250G>A, NM_000295.5:c.230C>T, NM_000295.5:c.194T>C, NM_000295.5:c.187C>T
SGCA	Muscular dystrophy, lin autosomal recessive 3	mb-girdle,	NM_000023.4:c.101G>A, NM_000023.4:c.229C>T, NM_000023.4:c.371T>C, NM_000023.4:c.518T>C, NM_000023.4:c.574C>T, NM_000023.4:c.662G>A, NM_000023.4:c.739G>A, NM_000023.4:c.850C>T, NM_000023.4:c.901_902insCC
SGCB	Limb-Girdle Muscular I Type 2E	Dystrophy,	NM_000232.5:c.552T>G, NM_000232.5:c.452C>G, NM_000232.5:c.341C>T, NM_000232.5:c.323T>G, NM_000232.5:c.299T>A, NM_000232.5:c.272G>T, NM_000232.5:c.272G>C
SGCG	Muscular dystrophy, lin type 2C	mb-girdle,	NM_000231.3:c.88delG, NM_000231.3:c.195_195+3delAGTA, NM_000231.3:c.505+1G>A, NM_000231.3:c.521delT, NM_000231.3:c.787G>A, NM_000231.3:c.848G>A



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
SGSH	Mucopolysaccharidisis (Sanfilippo A)	type IIIA NM_000199.5:c.1380deIT, NM_000199.5:c.1339G>A, NM_000199.5:c.1298G>A, NM_000199.5:c.1167C>A, NM_000199.5:c.8757deIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIG, NM_000199.5:c.757GeIGITInsGCAAGEGIGAG, NM_000199.5:c.357_345deICAAGEGIGATINSGCAAGEGIGAG, NM_000199.5:c.130G>A
SLC12A6	Agenesis of the Corpus with Peripheral Neuro (Andermann Syndrome	pathy
SLC17A5	Sialic acid storage diso infantile	rder, NM_012434.5:c.1259+16>A, NM_012434.5:c.9187>G, NM_012434.5:c.500T>C, NM_012434.5:c.406A>G, NM_012434.5:c.115C>T, NM_012434.5:c.43G>T
SLC25A1	3 Citrullinemia, Type II	NM_014251.3:c.1813C-T, NM_014251.3:c.1801G-T, NM_014251.3:c.1801G>A, NM_014251.3:c.1799dupA, NM_014251.3:c.159G>A, NM_014251.3:c.1411_412de(CT, NM_014251.3:c.1311+1G>A, NM_014251.3:2:1-1G>A, NM_014251.3:c.1417_145A, NM_014251.3:c.1078C-T, NM_014251.3:c.852_855de(TATG, NM_014251.3:c.674C>T, NM_014251.3:c.674C>A, NM_014251.3:c.615+5G>A, NM_014251.3:c.615+1G>C
SLC25A1	5 Ornithine translocase of	NM_014252.4:c.815C>T, NM_014252.4:c.824G>A
SLC26A2	Sulfate transporter-rel osteochondrodysplasia includes achondrogene 1B, atelosteogenesis ty diastrophic dysplasia, a recessive multiple epip dysplasia	AS, NM_000112.4:c.1361A>C, NM_000112.4:c.1535CA, NM_000112.4:c.1723delA, NM_000112.4:c.1878delG, NM_000112.4:c.1957T>A, NM_000112.4:c.2033G>T esis type ype 2, and
SLC26A4	Pendred syndrome	NM_000441.2:c.269C>T, NM_000441.2:c.281C>T, NM_000441.2:c.412G>T, NM_000441.2:c.554G>C, NM_000441.2:c.554C>C, NM_000441.2:c.262G>T, NM_000441.2:c.707T>C, NM_000441.2:c.594G>C, NM_000441.2:c.551 NM_000441.2:c.551 SIG NM_000441.2:c.554G>C, NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.915 NM_000441.2:c.917 NM_
SLC37A4	Glycogen storage disea	NM_001467.6:c.706_708delGTG, NM_001467.6:c.593A>T, NM_001467.6:c.352T>C, NM_001467.6:c.287G>A, NM_001467.6:c.1124-2_1124-1delAG, NM_001467.6:c.83G>A
SLC45A2	Oculocutaneous albini	sm, Type 4 NM_016180.5:c.1121deIT, NM_016180.5:c.986delC, NM_016180.5:c.469G>A
SLC4A11	Corneal Dystrophy and Perceptive Deafness	NM_001174089.2:c.2558G>A, NM_001174089.2:c.2557C>T, NM_001174089.2:c.2518A>G, NM_001174089.2:c.2480T>C, NM_001174089.2:c.2270C>T, NM_001174089.2:c.2216G>A, NM_001174089.2:c.2185_0129240pTATGACAC, NM_001174089.2:c.2176G>A, NM_001174089.2:c.1765C>T, NM_001174089.2:c.1815_017, NM_001174089.2:c.1415G>A, NM_001174089.2:c.1343G>A, NM_001174089.2:c.990_991insA, NM_001174089.2:c.589T>C, NM_001174089.2:c.577C>T, NM_001174089.2:c.425_432delGCTTCGCC
SLC6A8	Cerebral creatine defic syndrome 1	iency NM_005629.4:c.316_318delTTC, NM_005629.4:c.395G>T, NM_005629.4:c.1011C>G, NM_005629.4:c.1141G>C, NM_005629.4:c.1216_1218delTTC, NM_005629.4:c.1540C>T
SMN1	Spinal Muscular Atrop	hy Exon 7del
SMPD1	Niemann-Pick disease,	NM_000543.5:c.1564EG, NM_000543.5:c.353delC, NM_000543.5:c.4757-C, NM_000543.5:c.551C-T, NM_000543.5:c.5586_574del6CCCCCCAACCCCCTA, NM_000543.5:c.557C-T, NM_000543.5:c.5586_559insC, NM_000543.5:c.750C, NM_000543.5:c.737delT, NM_000543.5:c.730C-A, NM_000543.5:c.7570C, NM_000543.5:c.737delT, NM_000543.5:c.730C-A, NM_000543.5:c.7570C, NM_000543.5:c.737delT, NM_000543.5:c.730C-A, NM_000543.5:c.7570C, NM_000543.5:c.731204CAGCTGGGCTGGGCCCC, NM_000543.5:c.740G>A, NM_000543.5:c.731204CAGCTGGCCCC, NM_000543.5:c.740G>A, NM_000543.5:c.73120-A, NM_000543.5:c.740C>A, NM_000543.5:c.73120-A, NM_000543.5:c.740C>A, NM_000543.5:c.73120-A, NM_000543.5:c.740C>A, NM_000543.5:c.73120-A, NM_000543.5:c.740C>A, NM_000543.5:c.7320-A, NM_000543.5:c.740C>A, NM_000543.5:c.7320-A, NM_000543.5:c.730-A, NM_000543.5:c.740C>A, NM_000543.5:c.7320-A, NM_000543.5:c.740C>A, NM_000543.5:c.7320-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, NM_000543.5:c.730-A, N
STAR	Lipoid Congenital Adre Hyperplasia	nal NM_000349.3:c.772C>T, NM_000349.3:c.749G>A, NM_000349.3:c.577C>T, NM_000349.3:c.562C>T, NM_000349.3:c.559G>A, NM_000349.3:c.545G>T, NM_000349.3:c.545G>A



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
STRC	Deafness, autosomal re 16	Cessive NM_153700.2:c.5188C>T, NM_153700.2:c.5185C>T, NM_153700.2:c.5168_5171deITTCT, NM_153700.2:c.4545+1G>C, NM_153700.2:c.3556C>T
TAT	Tyrosinemia, Type II	NM_000353.3:c.1297C>T, NM_000353.3:c.1249C>T, NM_000353.3:c.668C>G, NM_000353.3:c.236-5A>G, NM_000353.3:c.169C>T
TCIRG1	Osteopetrosis, autoson recessive 1	al NM_006019.4:c.112_113delAG, NM_006019.4:c.179A>G, NM_006019.4:c.1213G>A, NM_006019.4:c.1331G>T, NM_006019.4:c.1674-1G>A, NM_006019.4:c.2236+1G>A, NM_006019.4:c.2415-3C>G
TFR2	Hemochromatosis, Typ Related	e 3, TFR2- NM_003227.4:c.2374G>A, NM_003227.4::2343G>A, NM_003227.4::2014C>T, NM_003227.4::1861=1872delGCCGTGGCCCAG, NM_003227.4::1655delC, NM_003227.4::1632_1633delGA, NM_003227.4::1473+1G>A, NM_003227.4::1469T>G, NM_003227.4::1403G>A, NM_003227.4::1330G>A, NM_003227.4::1235_1237delACA, NM_003227.4::186C>T, NM_003227.4::949C>T, NM_003227.4::240C>G, NM_003227.4::750C>G, NM_003227.4::515T>A, NM_003227.4::313C>T
тн	Tyrosine hydroxylase d	ficiency NM_000360.4:c.1388C>T, NM_000360.4:c.1341C>A, NM_000360.4:c.917G>A, NM_000360.4:c.733A>C, NM_000360.4:c.614T>C, NM_000360.4:c.605G>A
TMC1	Deafness, autosomal re	Cessive 7 NM_138691.3:c.100C>T, NM_138691.3:c.425G>A, NM_138691.3:c.454-1G>C, NM_138691.3:c.1165C>T, NM_138691.3:c.1763+3A>G, NM_138691.3:c.1842G>A, NM_138691.3:c.1960A>G
TMEM216	Joubert syndrome 2	NM_001173990.3:c.78_81delGAAC, NM_001173990.3:c.218G>A, NM_001173990.3:c.218G>T, NM_001173990.3:c.230G>C, NM_001173990.3:c.253C>T, NM_001173990.3:c.341T>G
TPP1	Ceroid lipofuscinosis, n 2/Spinocerebellar ataxi autosomal recessive 7	
TREX1	Aicardi-Goutieres syndi	ome 1 NM_033629.6:c.341G>A, NM_033629.6:c.490C>T
TRIM32	Bardet-Biedl syndrome	11 NM_012210.4:c.1459G>A, NM_012210.4:c.1559delC
TRIM37	Mulibrey nanism syndr	DME NM_015294.6:c.2212delG, NM_015294.6:c.2056C>T, NM_015294.6:c.1668-1G>C, NM_015294.6:c.1478_1479delAG, NM_015294.6:c.1411C>T, NM_015294.6:c.1346dupA, NM_015294.6:c.1037_1040dupAGAT, NM_015294.6:c.965G>T, NM_015294.6:c.745C>T, NM_015294.6:c.496_500delAGGAA, NM_015294.6:c.326G>C, NM_015294.6:c.22T>C
TSEN54	Pontocerebellar hypop	ASIA NM_207346.3:c.670_671deIAA, NM_207346.3:c.736C>T, NM_207346.3:c.887G>A, NM_207346.3:c.919G>T, NM_207346.3:c.1027C>T, NM_207346.3:c.1039A>T
TSFM	Combined Oxidative Phosphorylation Deficie	NM_005726.6:c.1_2delAT, NM_005726.6:c.21_22delGC, NM_005726.6:c.517delC, NM_005726.6:c.856C>T
TSHB	Congenital hypothyroid	ism NM_000549.5:c.94G>T, NM_000549.5:c.145G>A, NM_000549.5:c.205C>T
TSHR	Hypothyroidism, conge nongoitrous, 1	nital, NM_000369.5:c.100G>A, NM_000369.5:c.122G>C, NM_000369.5:c.202C>T, NM_000369.5:c.326G>A, NM_000369.5:c.484C>G, NM_000369.5:c.500T>A, NM_000369.5:c.1170T>G, NM_000369.5:c.1741_1742insC
TTN	Familial dilated cardion	NM_001267550.2:c.107889delA, NM_001267550.2:c.106070_106071delAT, NM_001267550.2:c.104092delC, NM_001267550.2:c.304092C7, NM_001267550.2:c.30271C-T, NM_001267550.2:c.88818_98821delTCCA, NM_001267550.2:c.50831dupT, NM_001267550.2:c.689344C-G, NM_001267550.2:c.50681dupT, NM_001267550.2:c.569344C-G, NM_001267550.2:c.32471-1G>A, NM_001267550.2:c.49314dupT, NM_001267550.2:c.39846-A, NM_001267550.2:c.32471-1G>A, NM_001267550.2:c.39344C-G, NM_001267550.2:c.32471-1G>A, NM_001267550.2:c.2303delAGCA, NM_001267550.2:c.25978G>A, NM_001267550.2:c.32471-1G>A, NM_001267550.2:c.15796C>T, NM_001267550.2:c.24724_4728delTGAAA, NM_001267550.2:c.3165-1G>T
ΤΤΡΑ	Ataxia with Vitamin E D	eficiency NM_000370.3:c.744delA, NM_000370.3:c.661C>T, NM_000370.3:c.575G>A
TYR	Albinism, oculocutaneo IA	US, type NM_00372.5:c.1A>G, NM_000372.5:c.15T>G, NM_000372.5:c.140G>A, NM_000372.5:c.164G>A, NM_000372.5:c.2305 A, NM_000372.5:c.2305 A, NM_000372.5:c.2305 A, NM_000372.5:c.2565 A, NM_000372.5:c.333G>A, NM_000372.5:c.568delG, NM_000372.5:c.586delG, NM_000372.5:c.558delG, NM_000372.5:c.558delG, NM_000372.5:c.558delG, NM_000372.5:c.558delG, NM_000372.5:c.111A>G, NM_000372.5:c.111A>G, NM_000372.5:c.125G>A, NM_000372.5:c.114>G, NM_000372.5:c.125G>A, NM_000372.5:c.114>G, NM_000372.5:c.114>G, NM_000372.5:c.125G>A, NM_000372.5:c.114>G, NM_000372.5:c.125G>A, NM_000372.5:c.114>G, NM_000372.5:c.125G>A, NM_000372.5:c.134G>A, NM_000372.5:c.125G>A, NM_000372.5:c.1466_14677N, NM_000372.5:c.12500_15011N5C
TYRP1	Oculocutaneous albinis	m, Type 3 NM_000550.3:c.105delT, NM_000550.3:c.176C>G, NM_000550.3:c.497C>G, NM_000550.3:c.1057delACAA, NM_000550.3:c.1067G>A, NM_000550.3:c.1101delA, NM_000550.3:c.1120C>T, NM_000550.3:c.1359T>G
UGT1A1	Crigler-Najjar Syndrome	NM_000463.3:c.44T>G, NM_000463.3:c.524T>A, NM_000463.3:c.674T>G
UGT1A8	Crigler-Najjar Syndrome	



List of variants analysed for the Geneseeker panel version 3.0, however, only variants classified as pathogenic and likely pathogenic at the time of analysis are reported.

GENE	DISEASE NAME	VAR NAME
USH1C	Usher syndrome, type 1C	NM_153676.4:c.2688_2695dupAATTCACC, NM_153676.4:c.2622_2623delCA, NM_153676.4:c.2547-1G>T, NM_153676.4:c.2362G>A, NM_153676.4:c.388G>A, NM_153676.4:c.238delC, NM_153676.4:c.238dupC, NM_153676.4:c.216G>A
USH2A	Usher syndrome, type 2A	NM_206933.4:c.15520-1G>A, NM_206933.4:c.15371delT, NM_206933.4:c.15089C-A, NM_206933.4:c.14926G>A, NM_206933.4:c.14903C-T, NM_206933.4:c.145197>C, NM_206933.4:c.12442C>A, NM_206933.4:c.1379delG, NM_206933.4:c.15274C>T, NM_206933.4:c.12234_12235delGA, NM_206933.4:c.13864G>A, NM_206933.4:c.1549-5, 11549-4int7, NM_206933.4:c.10636G>A, NM_206933.4:c.13864G>A, NM_206933.4:c.10073G>A, NM_206933.4:c.10636G>A, NM_206933.4:c.13964G>A, NM_206933.4:c.7346G>A, NM_206933.4:c.6862G>T, NM_206933.4:c.88431C>A, NM_206933.4:c.3975A>G, NM_206933.4:c.7544G>A, NM_206933.4:c.6862G>T, NM_206933.4:c.6874G>C, NM_206933.4:c.4384_304elCT, NM_206933.4:c.7543_5744delAG, NM_206933.4:c.3898delG, NM_206933.4:c.2396delCT, NM_206933.4:c.2396T>C, NM_206933.4:c.2276G>T, NM_206933.4:c.2167+5G>A, NM_206933.4:c.239delCT, NM_206933.4:c.2796T>C, NM_206933.4:c.2276G>T, NM_206933.4:c.2167+5G>A, NM_206933.4:c.2305delCT, NM_206933.4:c.777F>G
VPS13A	Choreoacanthocytosis	NM_033305.3:c.622C>T, NM_033305.3:c.2898T>G, NM_033305.3:c.3091delG, NM_033305.3:c.9109C>T, NM_033305.3:c.9275+1G>T
WAS	Wiskott-Aldrich syndrome	NM_000377.3:c.134C>T, NM_000377.3:c.173C>G, NM_000377.3:c.809T>C, NM_000377.3:c.814T>C, NM_000377.3:c.881T>C, NM_000377.3:c.1442T>A
WNT10A	Odontoonychodermal dysplasia/Schopf-Schulz- Passarge syndrome/Tooth agenesis, selective, 4	NM_025216.3:c.321C>A, NM_025216.3:c.347T>C, NM_025216.3:c.383G>A, NM_025216.3:c.697G>T
ХРА	Xeroderma pigmentosum A	Group NM_000380.4:c.731A>G, NM_000380.4:c.727C>T, NM_000380.4:c.619C>T, NM_000380.4:c.501delG, NM_000380.4:c.348T>A, NM_000380.4:c.323G>T
ZFYVE26	Spastic Paraplegia Type 15	 NM_015346.4:c.5485-165-A, NM_015346.4:c.542C>T, NM_015346.4:c.4936C>T, NM_015346.4:c.3412C>T, NM_015346.4:c.3642_3643insCCACCTTAG, NM_015346.4:c.3126G>A, NM_015346.4:c.3182deIT, NM_015346.4:c.28876>C, NM_015346.4:c.2114dupC, NM_015346.4:c.1477C>T

